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A B S T R A C T
Background
Epilepsy is a common neurological condition in which abnormal electrical discharges from the brain cause recurrent unprovoked
seizures. It is believed that with effective drug treatment, up to 70% of individuals with active epilepsy have the potential to become
seizure-free and go into long-term remission shortly after starting drug therapy, the majority of which may be able to achieve remission
with a single antiepileptic drug (AED).
The correct choice of first-line antiepileptic therapy for individuals with newly diagnosed seizures is of great importance. It is important
that the choice of AED for an individual is based on the highest-quality evidence available regarding the potential benefits and harms
of various treatments. It is also important to compare the efficacy and tolerability of AEDs appropriate to given seizure types.
Topiramate and carbamazepine are commonly used AEDs. Performing a synthesis of the evidence from existing trials will increase the
precision of results of outcomes relating to efficacy and tolerability, and may help inform a choice between the two drugs.
Objectives
To assess the effects of topiramate monotherapy versus carbamazepine monotherapy for epilepsy in people with partial-onset seizures
(simple or complex partial and secondarily generalised) or generalised onset tonic-clonic seizures (with or without other generalised
seizure types).
Search methods
We searched the Cochrane Epilepsy Group Specialized Register (14 April 2016), the Cochrane Central Register of Controlled Trials
(CENTRAL) (14 April 2016) andMEDLINE (Ovid, 1946 to 14 April 2016). We imposed no language restrictions. We also contacted
pharmaceutical companies and trial investigators.
Selection criteria
Randomised controlled trials in children or adults with partial-onset seizures or generalised-onset tonic-clonic seizures with or without
other generalised seizure types with a comparison of monotherapy with either topiramate or carbamazepine.
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Data collection and analysis
This was an individual participant data (IPD) review. Our primary outcome was ’time to withdrawal of allocated treatment’, and our
secondary outcomes were ’time to first seizure post randomisation’, ’time to 6-month remission, ’time to 12-month remission’ and
incidence of adverse events. We used Cox proportional hazards regression models to obtain trial-specific estimates of hazard ratios
(HRs) with 95% confidence intervals (CIs), and used the generic inverse variance method to obtain the overall pooled HRs and 95%
CIs.
Main results
IPD were available for 1151 of 1239 eligible individuals from two of three eligible studies (93% of the potential data). A small
proportion of individuals recruited into these trials had ’unclassified seizures;’ for analysis purposes, these individuals are grouped with
those with generalised onset seizures. For remission outcomes, a HR < 1 indicated an advantage for carbamazepine, and for first seizure
and withdrawal outcomes, a HR < 1 indicated an advantage for topiramate.
The main overall results, given as pooled HR adjusted for seizure type (95% CI) were: for time to withdrawal of allocated treatment
1.16 (0.98 to 1.38); time to first seizure 1.11 (0.96 to 1.29); and time to 6-month remission 0.88 (0.76 to 1.01). There were no
statistically significant differences between the drugs. A statistically significant advantage for carbamazepine was shown for time to 12-
month remission: 0.84 (0.71 to 1.00).
The results of this review are applicable mainly to individuals with partial-onset seizures; 85% of included individuals experienced
seizures of this type at baseline. For individuals with partial-onset seizures, a statistically significant advantage for carbamazepine was
shown for time to withdrawal of allocated treatment (HR 1.20, 95% CI 1.00 to 1.45) and time to 12-month remission (HR 0.84, 95%
CI 0.71 to 1.00). No statistically significant differences were apparent between the drugs for other outcomes and for the limited number
of individuals with generalised-onset tonic-clonic seizures with or without other generalised seizure types or unclassified seizures.
The most commonly reported adverse events with both drugs were drowsiness or fatigue, ‘pins and needles’ (tingling sensation),
headache, gastrointestinal disturbance and anxiety or depression The rate of adverse events was similar across the two drugs.
We judged the methodological quality of the included trials generally to be good; however, there was some evidence that the open-
label design of the larger of the two trials may have influenced the withdrawal rate from the trial. Hence, we judged the evidence
for the primary outcome of treatment withdrawal to be moderate for individuals with partial-onset seizures and low for individuals
with generalised-onset seizures. For efficacy outcomes (first seizure, remission), we judged the evidence from this review to be high for
individuals with partial-onset seizures and moderate for individuals with generalised-onset or unclassified seizures.
Authors’ conclusions
For individuals with partial-onset seizures, there is evidence that carbamazepine is less likely to be withdrawn and that 12-month
remission will be achieved earlier than with topiramate. No differences were found between the drugs in terms of the outcomes measured
in the review for individuals with generalised tonic-clonic seizures with or without other seizure types or unclassified epilepsy; however,
we encourage caution in the interpretation of these results due to the small numbers of participants with these seizure types.
We recommend that future trials should be designed to the highest quality possible and take into consideration masking, choice of
population, classification of seizure type, duration of follow-up, choice of outcomes and analysis, and presentation of results.
P L A I N L A N G U A G E S U M M A R Y
Topiramate versus carbamazepine as single drug treatment for epilepsy
Background
Epilepsy is a common disorder of the nervous system in which abnormal electrical discharges from the brain cause recurrent seizures
(physical convulsions or thought disturbances or a combination of these symptoms). We studied two types of epileptic seizures in this
review: generalised-onset seizures in which electrical discharges begin in one part of the brain and move throughout the brain, and
partial-onset seizures (also known as focal-onset seizures) in which the seizure is generated in and affects the same part of the brain.
Partial-onset seizures may become generalised (secondary generalisation) and move from one part of the brain to throughout the brain.
Up to 70% of individuals with active epilepsy have the potential to go into long-term remission shortly after starting drug therapy and
around 70% of these individuals can achieve seizure freedom using a single antiepileptic drug.
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This review applies to people with partial-onset seizures (with or without secondary generalisation) and people with tonic-clonic seizures,
a specific type of generalised-onset seizure, as the recommended treatments for these seizure types are similar.
Objective
Topiramate and carbamazepine are commonly used treatments for individuals with epilepsy. The aim of this review was to compare
how effective these drugs are at controlling recently diagnosed seizures, whether they are associated with side effects that may result in
individuals stopping the drug and to inform a choice between these drugs.
Methods
We searched for trials published April 2016. We assessed the evidence from three clinical trials that compared topiramate with
carbamazepine. We were able to combine data for 1151 people from two trials; we were not able to use the data from the remaining
trial, which included 88 participants.
Results
Most (85%) of the people included in the two trials experienced partial seizures, so the results of this review apply mainly to people with
this seizure type. Many of the remaining 15% of people experienced a seizure type which was difficult to classify as partial or generalised
(unclassified seizures). Considering only people with partial seizures, the results showed that those taking carbamazepine were more
likely to take their treatment for longer and to achieve a remission of 12 months duration earlier than those taking topiramate. No
differences were found between the drugs in individuals with generalised-onset or unclassified epilepsy.
The most common side effects reported by the participants during the trials were fatigue, ‘pins and needles’ (tingling sensation),
headache, gastrointestinal problems and anxiety or depression. These side effects were reported a similar number of times by people
taking topiramate or carbamazepine.
Quality of the evidence
For people with partial-onset seizures, we judged the quality of the evidence to be moderate to high. The design of the trials (whether
the people and treating clinicians knew which drug they were taking) may have influenced the how long a participant stayed on their
treatment. For the small number of people with generalised-onset or unclassified seizures, we judged the quality of the evidence to be
low to moderate.
Conclusions
Carbamazepine is currently recommended by experts for the treatment of individuals who are newly diagnosed with partial-onset
seizures and the results of this review do not provide any evidence to contradict this. More information is needed for people with
generalised-onset or unclassified seizures. We recommend that all future trials comparing these drugs, or any other antiepileptic drugs,
should be designed using high-quality methods, and the types of seizure of the people included in any trials should be classified very
carefully to ensure that the results are also of high quality.
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S U M M A R Y O F F I N D I N G S F O R T H E M A I N C O M P A R I S O N [Explanation]
Topiramate compared with carbamazepine for epilepsy
Population: Adults and children with epilepsy
Settings: Outpat ients
Intervention: Topiramate
Comparison: Carbamazepine
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
No. of participants
(studies)
Quality of the evidence
(GRADE)
Comments
Assumed risk Corresponding risk
Carbamazepine Topiramate
Time to treatment with-
drawal (adjusted for
epilepsy type)
Range of follow up: 0 to
2420 days
459 per 1000 509 per 1000
(452 to 571)
HR: 1.16
(0.98 to 1.38)
1129
(2 studies)
⊕⊕⊕©
moderate1
HR > 1 indicates a clin-
ical advantage for topi-
ramate
Time to treatment with-
drawal - stratified by
epilepsy type - partial
onset
Range of follow up: 0 to
2420 days
462 per 1000 525 per 1000
(462 to 593)
HR: 1.20
(1.00 to 1.45)
974
(2 studies)
⊕⊕⊕©
moderate1
HR > 1 indicates a clin-
ical advantage for topi-
ramate
Time to treatment with-
drawal - stratified by
epilepsy type - gener-
alised-onset or unclas-
sified epilepsy
Range of follow up: 0 to
1446 days
433 per 1000 400 per 1000
(264 to 566)
HR: 0.90
(0.54 to 1.47)
155
(2 studies)
⊕⊕©©
low1,2
HR > 1 indicates a clin-
ical advantage for topi-
ramate
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The assumed risk is calculated as the event rate in the carbamazepine treatment. The corresponding risk (and its 95% CI) is based on the assumed risk in the comparison
group and the relative effect of the intervent ion (and its 95% CI).
The corresponding risk is calculated as the assumed risk x the relat ive risk (RR) of the intervent ion where RR = (1 - exp(HR x ln(1 - assumed risk)))/ assumed risk.
CI: Conf idence interval; HR: Hazard Ratio
GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our conf idence in the est imate of ef fect.
M oderate quality: Further research is likely to have an important impact on our conf idence in the est imate of ef fect and may change the est imate.
Low quality: Further research is very likely to have an important impact on our conf idence in the est imate of ef fect and is likely to change the est imate.
Very low quality: We are very uncertain about the est imate.
1. Downgraded once for risk of bias, the larger of the two studies was open-label (SANAD A 2007) and may have inf luenced
the withdrawal rates of the trial.
2. Downgraded once for imprecision and applicability, lim ited information on generalised seizure types and most part icipants
do not have a classif ied seizure type in this subgroup so the interpretat ion of this seizure type is unclear.
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B A C K G R O U N D
Description of the condition
Epilepsy is a common neurological condition in which abnormal
electrical discharges from the brain cause recurrent, unprovoked
seizures. Epilepsy is a disorder comprising many heterogeneous
seizure types, with an estimated incidence of 33 to 57 per 100,000
person-years worldwide (Annegers 1999; Hirtz 2007;MacDonald
2000; Olafsson 2005; Sander 1996), accounting for between 1%
and 5% of the global burden of disease (Murray 1994; Sander
1996). The lifetime risk of epilepsy onset is estimated to be 1300 to
4000 per 100,000 person-years (Hauser 1993; Juul-Jenson 1983).
Recently, around 42 million individuals worldwide were reported
to have active epilepsy worldwide (Global Disease 2015); however,
country-specific prevalence and incidence rates are thought to vary
considerably, with higher rates in resource-poor countries (Bell
2014). It is thought that the lifetime prevalence could be as much
as 70 million people worldwide (Ngugi 2010). Experts believe
that with effective drug treatment, up to 70% of individuals with
active epilepsy have the potential to go into long-term remission
shortly after starting drug therapy (Cockerell 1995; Hauser 1993;
Sander 2004), and around 70% of these individuals can achieve
seizure freedom using antiepileptic drug (AED) monotherapy (
Cockerell 1995). Current UK National Institute for Health and
Care Excellence (NICE) guidelines recommend that both adults
and children with epilepsy be treated with monotherapy wherever
possible (NICE 2012). The remaining 30% of individuals who
experience refractory or drug-resistant seizures will often require
treatment with combinations of AEDs or alternative therapies,
such as epilepsy surgery (Kwan 2000).
We studied two seizure types in this review; generalised onset
seizures in which electrical discharges begin in one part of the
brain and move throughout the brain, and partial onset seizures in
which the seizure is generated in and affects one part of the brain
(the whole hemisphere of the brain or part of a lobe of the brain).
Description of the intervention
Carbamazepine was amongst the earliest of the ’traditional’ drugs
licensed for the treatment of epileptic seizures and has been com-
monly used as monotherapy for partial-onset and generalised-
onset seizures for over 30 years (Shakir 1980). Topiramate is a
’second-generation’ AED, licensed as monotherapy for epileptic
seizures following demonstrations of efficacy in dose-controlled
studies compared with ’traditional’ AEDs such as carbamazepine
and sodium valproate (Gilliam 2003; Privitera 2003; SANAD
A 2007; SANAD B 2007). Comparative trials have also shown
newer AEDs, such as topiramate, to be generally well tolerated
as monotherapy in both adults and children and associated with
fewer adverse events, fewer serious adverse events, and fewer drug
interactions with concomitant AEDs and other concomitant med-
ications than ’traditional’ first-line AEDs such as carbamazepine
(French 2007).
Evidence regarding the teratogenic effects (disturbances to foetal
development) of carbamazepine and topiramate is inconclusive.
Experts believe that the risk of congenital malformation may be
higher in women taking carbamazepine than in the general popu-
lation (Meador 2008; Morrow 2006; Weston 2016), and studies
have associated carbamazepine with neural tube defects (Matlow
2012). The risk of malformations is thought to be lower for
women taking topiramate monotherapy than for those taking car-
bamazepine monotherapy (Hunt 2008; Meador 2008; Morrow
2006), but the risk of malformation may increase in women tak-
ing topiramate as a component of polytherapy (Hunt 2008). It is
unclear whether taking topiramate or carbamazepine during preg-
nancy has any negative neurodevelopmental effects on the child
(Bromley 2014).
Current UK guidelines for adults and children recommend carba-
mazepine or lamotrigine as a first-line treatment for newly onset
partial seizures, and sodium valproate for newly onset generalised
tonic-clonic seizures (with or without other generalised seizure
types) (NICE 2012). Carbamazepine may be a suitable second-
line treatment for generalised-onset tonic-clonic seizures, but may
exacerbate myoclonic or absence seizures (Liporace 1994; Shields
1983; Snead 1985). Topiramate is mainly recommended for ad-
junctive use, but may be considered as a second-line treatment for
both partial and generalised seizures if first-line treatments have
failed or are unsuitable.
How the intervention might work
AEDs suppress seizures by reducing neuronal excitability (disrup-
tion of the usual mechanisms of a neurone within the brain, which
may lead to an epileptic seizure) (MacDonald 1995). Both topi-
ramate and carbamazepine are considered broad-spectrum treat-
ments suitable for many seizure types. Carbamazepine has an anti-
convulsant mechanism that works by blocking ion channels, bind-
ing with neurotransmitter receptors, or inhibiting the metabolism
or reuptake of neurotransmitters (Brodie 1996; Ragsdale 1991).
The mechanisms of action of topiramate are not fully understood
butmay include the inhibition of voltage-dependent sodiumchan-
nels and the enhancement or modulation of gamma-aminobu-
tyric acid-A by action at a unique modulatory site (Coulter 1993;
White 1997).
Why it is important to do this review
With evidence that up to 70% of individuals with active epilepsy
have the potential to go into long-term remissionof seizures shortly
after starting drug therapy (Cockerell 1995; Hauser 1993; Sander
2004), the correct choice of first-line antiepileptic therapy for in-
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dividuals with newly diagnosed seizures is of great importance. It
is important that clinicians are able to choose themost appropriate
AED for an individual using the highest-quality evidence available
regarding the potential benefits and harms of various treatments.
It is also important to compare the efficacy and tolerability of
AEDs appropriate to given seizure types. Performing a synthesis of
the evidence from existing trials will increase the precision of the
results of outcomes relating to efficacy and tolerability, and may
help inform a choice between drugs.
There are difficulties in undertaking a systematic review of epilepsy
monotherapy trials, as the important efficacy outcomes require
analysis of time-to-event data (e.g. time to first seizure after ran-
domisation). Although methods have been developed to synthe-
sise time-to-event data using summary information (Parmar 1998;
Williamson 2002), the appropriate statistics are not commonly
reported in published epilepsy trials (Nolan 2013a). Furthermore,
although most epilepsy monotherapy trials collect seizure data,
the definitions and reporting of outcomes are inconsistent. For
example, trials may report time to 12-month remission but not
time to first seizure or vice versa, or some trials may define time to
first seizure from the date of randomisation whereas others use the
date of achieving maintenance dose. Trial investigators have also
adopted differing approaches to data analysis, particularly with
respect to the censoring of time-to event data. To overcome these
problems, we performed this review using individual participant
data (IPD). This review is one in a series of Cochrane IPD reviews
investigating pair-wise monotherapy comparisons (Marson 2000;
Nolan 2013b; Nolan 2013c; Nolan 2013d; Nolan 2015a; Nolan
2015b). The data in these reviews are also included in a network
meta-analysis and a pending networkmeta-analysis update (Tudur
Smith 2007; see Nolan 2014 for the protocol of the update).
O B J E C T I V E S
To assess the effects of topiramate monotherapy versus carba-
mazepine monotherapy for epilepsy in people with partial-onset
seizures (simple or complex partial and secondarily generalised)
or generalised-onset tonic-clonic seizures (with or without other
generalised seizure types).
M E T H O D S
Criteria for considering studies for this review
Types of studies
1. Studies must be randomised controlled trials (RCTs) using
either an adequate method of allocation concealment (e.g. sealed
opaque envelopes) or a quasi-randomised method of allocation
(e.g. allocation by date of birth)
2. Studies must be of parallel design; cross-over studies are not
an appropriate design for measuring the long-term outcomes of
interest in this review (see Types of outcome measures)
3. Studies must include a comparison of topiramate
monotherapy with carbamazepine monotherapy in individuals
with epilepsy; therefore, cluster randomised studies are not an
eligible design
We included studies regardless of blinding method (unblinded,
single-blind or double-blind).
Types of participants
1. We included trials recruiting children or adults with partial-
onset seizures (simple partial, complex partial, or secondarily
generalised tonic-clonic seizures) or generalised-onset tonic-
clonic seizures (as a primary generalised seizure type), with or
without other generalised seizure types (e.g. absence, myoclonic
etc.)
2. We excluded studies that recruited only individuals with
other generalised seizure types, without generalised tonic-clonic
seizures (such as studies recruiting only individuals with a
diagnosis of absence seizures or juvenile myoclonic epilepsy, etc.)
due to differences in first-line treatment guidelines (NICE 2012)
3. We included individuals who had a new diagnosis of
epilepsy or who had experienced a relapse following antiepileptic
monotherapy withdrawal only, due to differences in first-line
treatment guidelines for individuals with refractory epilepsy (
NICE 2012)
Types of interventions
Included studies had to have made a randomised comparison of
topiramate and carbamazepine (of any dose) as monotherapy. If
studies included additional arms of treatments, other than topira-
mate and carbamazepine, we did not include these treatment arms
in our analysis of the review.
Types of outcome measures
Below is a list of outcomeswe investigated in this review. Reporting
of these outcomes in the original study report was not an eligibility
requirement for this review.
Primary outcomes
Time to withdrawal of allocated treatment after randomisation
(retention time). This is a combined outcome reflecting both ef-
ficacy and tolerability, as the following may cause withdrawal of
treatment: continued seizures, side effects, non-compliance or the
initiation of additional add-on treatment (i.e. allocated treatment
had failed). This is an outcome to which the participant makes a
contribution and is the primary outcome measure recommended
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by the Commission on Antiepileptic Drugs of the International
League Against Epilepsy (ILAE 1998; ILAE 2006).
Secondary outcomes
1. Time to first seizure recurrence post randomisation
2. Time to achieve 6-month remission (seizure-free period)
post randomisation
3. Time to achieve 12-month remission (seizure-free period)
post randomisation
4. Incidence of adverse events (all reported, whether related or
unrelated to treatment) and adverse events leading to treatment
withdrawal
Search methods for identification of studies
Electronic searches
We searched the following databases.
• Cochrane Epilepsy Group Specialized Register (14/04/
2016) using the search strategy shown in Appendix 1.
• Cochrane Central Register of Controlled Trials
(CENTRAL) via the Cochrane Register of Studies Online
(CRSO, 14/04/2016) using the search strategy shown in
Appendix 2.
• MEDLINE (Ovid, 1946 to 14/04/2016) using the search
strategy shown in Appendix 3.
• ClinicalTrials.gov (14/04/2016) using the search terms:
topiramate AND carbamazepine AND epilepsy.
• WHO International Clinical Trials Registry Platform
(ICTRP, 14/04/2016) using the search terms: topiramate AND
carbamazepine AND epilepsy NOT NCT*.
Searching other resources
We handsearched the reference lists of retrieved studies for addi-
tional reports of relevant studies. We contacted Novartis (formerly
Ciba Geigy, manufacturers of carbamazepine), Janssen Pharma-
ceuticals (manufacturers of topiramate) and the original investi-
gators of relevant trials to identify any additional published or un-
published data.
Data collection and analysis
Selection of studies
Two review authors (SJN, AGM) independently assessed studies
for inclusion, resolving any disagreements by discussion.
Data extraction and management
We requested the following IPD for all studies meeting our inclu-
sion criteria.
• Design and methods.
◦ Method of generation of random list.
◦ Method of allocation concealment.
◦ Stratification factors.
◦ Blinding methods.
• Participant covariates.
◦ Sex.
◦ Age.
◦ Seizure types.
◦ Time between first seizure and randomisation.
◦ Number of seizures prior to randomisation (with
dates).
◦ Presence of neurological signs.
◦ Electroencephalographic (EEG) results.
◦ Computerised tomography/magnetic resonance
imaging (CT/MRI) results.
• Follow-up data.
◦ Treatment allocation.
◦ Date of randomisation.
◦ Dates of follow-up.
◦ Dates of seizures post randomisation or seizure
frequency data between follow-up visits.
◦ Dates of treatment withdrawal and reasons for
treatment withdrawal.
◦ Dose.
◦ Dates of dose changes.
If IPD were not available for a study, we intended to carry out
an assessment to see whether the trial reported any relevant aggre-
gate-level data or whether we could indirectly estimate such data
using the methods of Parmar 1998 and Williamson 2002. Where
graphical time-to-event data (e.g. Kaplan-Meier curves) were pub-
lished, with or without corresponding effective numbers at risk,
we intended to use a macro-enabled Microsoft Excel spreadsheet
to indirectly estimate hazard ratios (HRs) or make use of graphical
digitising software, if appropriate and the quality of the published
graph(s) allowed (Excel 2010; Tierney 2007).
We accepted follow-up and outcome data in any format provided.
One trial provided dates of seizures after randomisation (Privitera
2003) and one study provided the number of seizures recorded at
each follow-up visit (SANADA2007). To enable the calculationof
time-to-event outcomes for studies that provided seizure data only
in terms of the number of seizures recorded between each follow-
up visit rather than the specific dates of seizures, we applied linear
interpolation to approximate dates of seizures between follow-up
visits. For example, if the trial recorded four seizures between two
visits that occurred on 1 March 2010 and 1 May 2010 (interval
of 61 days), then we estimated that the first seizure took place
around 13March 2010. This method allowed the computation of
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an estimate of the time to 6- and 12-month remission for studies
of sufficient length.
We calculated time to first seizure from the date of randomisation
to the date that we estimated the first seizure to have occurred. If
seizure data were missing for a particular visit, we censored these
outcomes at the previous visit. We also censored these outcomes if
the individual died or if follow up ceased prior to the occurrence
of the event of interest.
We calculated time to 6- and 12-month remission from the date of
randomisation to the date (or estimated date) that the individual
had first been free of seizures for 6 or 12 months, respectively (e.g.
365 days for those who achieve 12-month remission immediately).
If the person had one or more seizure during the trial, a 6- or 12-
month seizure-free period could also occur between the estimated
date of the last seizure during the trial and a period of 6 or 12
months of seizure freedom.
We calculated time to treatment withdrawal as the date of ran-
domisation to the date of withdrawal from the trial. For the time-
to-event analysis, we defined an ’event’ as the withdrawal of the
allocated treatment because of reasons related to the treatment
(i.e. lack of efficacy, occurrence of adverse events, or both; non-
compliance with the treatment regimen; withdrawal of consent
from the trial; etc). We censored the outcome if treatment was
withdrawn for reasons not related to the trial treatment (i.e. loss
to follow-up, death (not treatment or epilepsy related), etc.). We
also censored individuals who were still on allocated treatment at
the date of the end of follow-up.
We considered documented reasons for withdrawal on a case-by-
case basis for relation to treatment; two authors (SJN, MS) inde-
pendently classified reasons for withdrawals as events or censored,
and resolved any disagreements by discussion. If included trials
classified the reasons for withdrawal as events or censored differ-
ently from our definitions, we conducted sensitivity analyses to
account for differences in the definition of a withdrawal ’event’.
Assessment of risk of bias in included studies
Two review authors (SJN,MS) independently assessed all included
studies for risk of bias, resolving any disagreements by discussion.
In the event of the presence of a high risk of bias in included trials
(due to inadequate allocation concealment or lack of blinding),
we intended to conduct sensitivity analyses excluding these trials.
Measures of treatment effect
We measured all outcomes in this review as time-to-event out-
comes using the HR as the measure of treatment effect. We cal-
culated 95% confidence intervals (CIs) to provide a measure of
precision of the treatment effect estimate. We calculated all out-
comes from IPD provided, where possible, and if IPD were not
available, we intended to use extracted or estimated aggregate data
from published trials if possible.
We considered adverse events narratively rather than formally in
analyses due to anticipated differences in the format of adverse
event reporting in the included studies.
Unit of analysis issues
Cross-over and cluster randomised studies were not an eligible
design for this review (see Types of studies).
If eligible studies included multiple treatment arms of different
topiramate or carbamazepine doses, we pooled study arms of the
same treatment in primary analyses to allow a comparison of top-
iramate and carbamazepine. For one trial, which randomised par-
ticipants to two doses of topiramate (100 mg/day or 200 mg/day),
we performed a secondary analysis to analyse the different doses
compared with carbamazepine (Privitera 2003).
It was not within the scope of this review to compare directly dif-
ferent doses of the same treatment (e.g. the two doses of topira-
mate).
Dealing with missing data
For each trial that supplied IPD, we performed the following con-
sistency checks.
1. We cross-checked study details against any published report
of the study and contacted the data providers if we found
missing data, errors or inconsistencies.
2. If the data providers could not resolve inconsistencies
between IPD and published data, we intended to either perform
sensitivity analyses or exclude the data from the meta-analysis,
depending on the extent of the inconsistencies.
3. If possible, we reviewed the chronological randomisation
sequence and checked the balance of prognostic factors, taking
account of any stratification factors in the randomisation
procedure.
Assessment of heterogeneity
We assessed heterogeneity statistically using the Q test (P < 0.10
for significance) and the I2 statistic (values greater than 50% in-
dicating considerable heterogeneity), with output produced using
the generic inverse variance approach available in ReviewManager
(Higgins 2003; RevMan 2014). We also assessed heterogeneity
visually by inspecting forest plots.
Assessment of reporting biases
Two review authors (SJN,MS) undertook full quality and ’Risk of
bias’ assessments according to methods outlined in the Cochrane
Handbook for Systematic Reviews of Interventions (Higgins 2011).
In theory, a review using IPD should overcome issues of reporting
biases, as unpublished data can be provided and unpublished out-
comes calculated. We requested all study protocols with IPD. If
we suspected any selective reporting bias, we intended to explore
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the extent of the bias using the Outcome Reporting Bias In Trials
(ORBIT) classification system (Kirkham 2010).
Data synthesis
For all outcomes, we investigated the relationship between the
time-to-event and treatment effect of the AEDs. We used Cox
proportional hazards regression models to obtain trial-specific es-
timates of log (HR) or treatment effect and associated standard
errors (SAS® software, version 9.3, Copyright, SAS Institute Inc.
SAS and all other SAS Institute Inc. product or service names are
registered trademarks or trademarks of SAS Institute Inc., Cary,
NC, USA). Themodel assumes that the ratio of hazards (risks) be-
tween the two treatment groups is constant over time (i.e. hazards
are proportional). We tested this proportional hazards assumption
of the Cox regression model for each outcome of each trial by vi-
sually inspecting the crossing of survival plots for each trial and by
testing the statistical significance of a time-varying covariate in the
model with a conservative judgement of P < 0.10 for significance.
We evaluated overall pooled estimates of HRs (with 95% CIs) us-
ing the generic inverse variance method. We expressed results as
HRs and 95% CIs. We used a fixed-effect model and, if consid-
erable heterogeneity was present (I2 statistic > 50%), we intended
to repeat the analysis using a random-effects model.
By convention, an HR greater than 1 indicated that an event
was more likely to occur earlier with topiramate than with carba-
mazepine. Hence, for time to withdrawal of allocated treatment
or time to first seizure, a HR greater than 1 indicates a clinical
advantage for carbamazepine (e.g. a HR of 1.2 would suggest a
20% increase in risk of withdrawal from topiramate compared
with carbamazepine), and for time to 6-month, 12- month and
24-month remission, a HR greater than 1 indicates a clinical ad-
vantage for topiramate (i.e. the seizure-free period occurs earlier
with topiramate than with carbamazepine).
We conducted our analysis on an intention-to-treat basis (i.e. we
analysed participants in the group to which they were randomised,
irrespective of which treatment they actually received). Therefore,
for the time-to-event outcomes ’time to 6-month remission’, ’time
to 12-month remission’ and ’time to first seizure post randomisa-
tion’, we did not censor participants if treatment was withdrawn.
Intention-to-treat analyses often tend to suggest equivalence be-
tween treatments (i.e. no statistically significant difference), so we
intended to undertake a secondary per-protocol analysis as a sen-
sitivity analysis if the primary analyses suggest equivalence. In this
case, participants would be censored at the time of drug with-
drawal for seizure outcomes.
Subgroup analysis and investigation of heterogeneity
Due to the strong clinical belief that some AEDs are more effec-
tive for some seizure types than for others (see Description of the
intervention and How the intervention might work), we intended
to stratify all analyses by epilepsy type (partial-onset versus gener-
alised-onset), according to the classification of main seizure type
at baseline. We classified partial seizures (simple or complex) and
partial secondarily generalised seizures as partial epilepsy.We clas-
sified primarily generalised tonic-clonic seizures, with or without
other seizure types, as generalised epilepsy.
Seizure type was missing (unclassified) for 89 participants from
SANADA 2007 and 13 participants were classified as having gen-
eralised-onset seizures, even though the trial was designed to in-
clude only participants with partial-onset seizures. Also, only 73
participants from Privitera 2003 were classified as having gener-
alised-onset seizures (by design the majority of participants form-
ing the comparison of carbamazepine and topiramate had partial-
onset seizures, see Characteristics of included studies for more de-
tails).
Therefore, for the purposes of subgroup analysis, we felt it would
be more appropriate to compare the subgroup of participants with
partial-onset epilepsy and the subgroup with ’generalised-onset
or unclassified epilepsy’. We conducted a Chi2 test of interaction
between treatment and epilepsy type.
If further trials recruiting individuals with generalised seizure types
are included in updates of this review, we hope to perform a sub-
group analysis of partial-onset versus generalised-onset epilepsy.
If we deemed considerable statistical heterogeneity to be present
(I2 statistic > 50%), we intended to perform meta-analyses using
a random-effects model in addition to a fixed-effect model and
present the results of both models. Also, if possible, we considered
investigating factors that could contribute to heterogeneity (e.g.
participant covariates, trial design as described in Data extraction
and management) via further subgroup analyses or via metaregres-
sion models.
Sensitivity analysis
In addition to the planned sensitivity analyses we intended to per-
form sensitivity analyses if we considered studies to be at high risk
of bias (see Assessment of risk of bias in included studies), if we
found inconsistencies between published study reports and the
IPD provided (see Dealing with missing data) or if trials included
multiple treatment arms (see Unit of analysis issues). We also in-
tended to perform several sensitivity analyses to test the robustness
of our results in relation to the characteristics of the included trials.
1. Definition of time to treatment withdrawal: we classified
reasons for withdrawal that were related to the trial treatment as
’events’ and reasons not related to treatment as ’censored’ in
analyses of ’time to treatment withdrawal.’ If included trials
classified the reasons for withdrawal as events or censored
differently from us, we conducted sensitivity analyses to account
for differences in the definition of a withdrawal ’event’ (SANAD
A 2007).
2. Aggregate data: this is an IPD review; we will include IPD
only in all primary analyses. We were unable to extract any
aggregate data from the one trial included in this review for
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which no IPD were available (Resendiz-Aparicio 2004), but if we
are able to extract aggregate data from trials included in future
updates of this review (see Data extraction and management), we
intend to combine aggregate data with IPD in sensitivity
analyses and examine the differences between the IPD and
combined analyses.
3. Open-label extension: one included trial comprised a 6-
month double-blind phase followed by an open-label extension
phase (Privitera 2003). As both blinded and open-label trials are
eligible for inclusion in this review, by our intention-to-treat
approach, we included the entire follow-up period in analysis .
We also performed a sensitivity analysis of outcomes of time to
withdrawal of allocated treatment, time to first seizure and time
to 6-month remission, censoring these outcomes at the end of
the double-blind phase and comparing results to those from the
primary analysis (we note that in this analysis, time to 6-month
remission becomes time to immediate 6-month remission when
considered over a 6-month period).
4. Misclassification of seizure type: this is a recognised problem
in epilepsy, whereby some people with generalised seizures have
been mistakenly classed as having partial-onset seizures and vice
versa. Such misclassification had an impact on the results of three
reviews in a series of pair-wise reviews of monotherapy in
epilepsy comparing carbamazepine, phenobarbitone, phenytoin
and sodium valproate, in which around 30% to 50% of
participants analysed may have had their seizure type
misclassified as generalised onset (Nolan 2013b; Nolan 2015a;
Nolan 2015b). Given the potential biases introduced into these
three reviews, we examined the distribution of age at onset for
individuals with generalised seizures in the trials included in this
review, to assess the potential impact of misclassification of
seizure type on the outcomes. (There is clinical evidence that
individuals with generalised-onset seizures are unlikely to have
an ’age of onset’ greater than 25 to 30 years (Malafosse 1994)).
Given that most of the individuals recruited to the trials included
in the present review experienced partial-onset seizures, this
sensitivity analysis was not appropriate for this review and
instead we performed a subgroup analysis of partial-onset versus
generalised-onset or unclassified epilepsy (see Subgroup analysis
and investigation of heterogeneity). For updates of the review, if
future trials recruit more individuals with generalised-onset
seizures, we intend to perform a sensitivity analysis in two ways:
a) we will reclassify individuals with generalised seizure types and
age at onset greater than 30 years as having partial-onset seizures,
and we will repeat subgroup analyses;
b) we will reclassify individuals with generalised seizure types and
age at onset greater than 30 years into an ’uncertain seizure type’
group, and we will repeat subgroup analyses with three groups.
’Summary of findings’ table
We have presented two ’Summary of findings’ tables. The first
presents the summary of the main comparison reporting the pri-
mary outcome of ’time to treatment withdrawal’ in the subgroups
of participants with partial-onset epilepsy and generalised-onset
or unclassified epilepsy overall for all participants, adjusted by
epilepsy type.
The second ’Summary of findings’ table reports the secondary out-
comes of ’time to first seizure’ and ’time to 12-month remission’ in
the subgroups of participants with partial-onset epilepsy and gen-
eralised-onset or unclassified epilepsy overall for all participants,
adjusted by epilepsy type.
We determined the quality of the evidence using the GRADE ap-
proach (GRADEPro 2004), whereby we downgraded evidence in
the presence of a high risk of bias in at least one trial, indirect-
ness of the evidence, unexplained heterogeneity or inconsistency,
imprecision of results or high probability of publication bias. We
downgraded evidence by one level if we considered the limitation
to be serious and two levels if we considered it to be very serious.
As per the GRADE approach, we could also upgrade evidence if
it showed a large treatment effect with no obvious biases or if a
dose-response effect existed.
R E S U L T S
Description of studies
Results of the search
We identified 131 records from the databases and search strategies
outlined in Electronic searches.We found no additional records by
handsearching and checking the reference lists of included studies.
We removed 30 duplicate records and screened 101 records (title
and abstract) for inclusion in the review. We excluded 85 records
based on title and abstract, and assessed 16 records describing 4
full-text articles for inclusion in the review. We excluded 3 records
linked to a single study from the review (see Excluded studies
below) and included 3 studies in the review described in 13 records
(see Included studies below). See Figure 1 for a PRISMA study
flow diagram.
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Figure 1. Study flow diagram.
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Included studies
We included three studies in the review (Privitera 2003; Resendiz-
Aparicio 2004; SANAD A 2007).
One trial recruited individuals over the age of six years (Privitera
2003) and another trial recruited individuals over the age of four
years (SANADA2007). The third trial recruited children between
the ages of 6 and 18 years (Resendiz-Aparicio 2004).
One trial recruited individuals with partial seizures with or with-
out secondary generalisation (Resendiz-Aparicio 2004). SANAD
A 2007 was designed to recruit individuals with partial seizures
only but some individuals with generalised-onset or unclassified
seizures were recruited; we examine this seizure classification in
subgroup analysis. Privitera 2003 was designed in two strata based
on whether the recommended treatment would be carbamazepine
or sodium valproate. Within the two strata, participants were
randomised to topiramate 100 mg/day or 200 mg/day, or car-
bamazepine/sodium valproate depending on the stratum. Only
the carbamazepine stratum (participants randomised to carba-
mazepine or one of the two doses of topiramate) was eligible for
the randomised comparison in this review. Themajority of partici-
pants within this stratum had partial seizures but some individuals
with generalised-onset or unclassified seizures were also recruited;
we examine this seizure classification in subgroup analysis.
Two trials recruited individuals with new-onset seizures (Privitera
2003; Resendiz-Aparicio 2004) and one trial recruited individuals
with new-onset, relapsed or recurrent seizures (failure of an AED
not randomised in the trial) (SANAD A 2007).
All three trials were conducted in a multicentre setting; Resendiz-
Aparicio 2004 was conducted in Mexico, SANAD A 2007 was
conducted in the UK and Privitera 2003 was conducted in centres
across the USA, Canada, Europe and South America.
IPD were available for two trials randomising 1151 participants to
carbamazepine or topiramate (Privitera 2003; SANAD A 2007).
For the third trial, which recruited 88 participants, we were unable
to contact the original authors and so IPDcould not be included in
this review (Resendiz-Aparicio 2004). Overall, IPD were available
for 93% of the total eligible 1239 participants.
Data were available for the following participant characteristics
(percentage of 1151 participants with data available): drug ran-
domised (100%), sex (98%, data missing for 18 participants in
SANAD A 2007), age at randomisation (98%, data missing for
18 participants in SANAD A 2007), number of seizures in six
months prior to randomisation (98%, missing for 21 participants
in SANAD A 2007) and seizure type (92%, data missing for 89
participants in SANAD A 2007).
Results of neurological examinations were available for 738 of 756
participants (98%) from SANADA 2007 (data for 18 participants
missing). This information was not available for Privitera 2003.
No information was available from either trial regarding EEG or
, CT/MRI results and time since first seizure to randomisation.
See the Characteristics of included studies and Table 1 for further
details.
Excluded studies
We excluded one study described in three records (Kang 2007).
This study recruited children with only benign rolandic epilepsy,
which was an ineligible seizure type for this review.
Risk of bias in included studies
For further details, see the Characteristics of included studies and
Figure 2.
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Figure 2. ’Risk of bias’ summary: review authors’ judgements about each risk of bias item for each included
study.
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Allocation
As all three trials described adequate methods of generation of a
random list we judged them to be at low risk of bias; Privitera
2003 used computer generated block randomisation, Resendiz-
Aparicio 2004 used random number tables and SANAD A 2007
used minimisation.
SANAD A 2007 used telephone randomisation to a central al-
location service, and so we judged the study to be at low risk of
bias for allocation concealment. As the other two trials did not
describe a method of allocation concealment we judged them to
be at unclear risk of bias.
Blinding
We judged the two open-label trials to be at high risk of perfor-
mance and detection bias (Resendiz-Aparicio 2004; SANAD A
2007). The third trial comprised a six-month double-blind phase
followed by an open-label extension phase; it was unclear if out-
come assessors were blinded in this trial.
Incomplete outcome data
In theory, a review using IPD should overcome issues of attrition
bias as unpublished data can be provided, unpublished outcomes
calculated, and all randomised participants can be analysed by an
intention-to-treat approach. Both trials providing IPD (Privitera
2003; SANAD A 2007) for all randomised individuals reported
the extent of follow up for each individual. We queried any miss-
ing data with the original trial authors. From the information pro-
vided by the authors, we deemed the small amount of missing
data present (see Included studies) to be missing at random and
considered that it did not affect our analysis.
For the trial for which no IPD were provided, we included only
those participants who completed the trial in analyses; this is not
an intention-to-treat approach so we judged this trial to be at high
risk of attrition bias (Resendiz-Aparicio 2004).
Selective reporting
In theory, a review using IPD should overcome issues of reporting
biases as unpublished data can be provided and unpublished out-
comes calculated. We requested trial protocols in all IPD requests
and protocols were provided for Privitera 2003 and SANAD A
2007. We received sufficient IPD to calculate all outcomes for
both trials.
For the trial for which no IPD were provided, no protocol was
available and the trial publication was translated from Spanish by
SJN. We judged seizure outcomes and adverse events to be well
reported and to be at low risk of selective reporting bias (Resendiz-
Aparicio 2004).
Other potential sources of bias
We identified no other potential sources of bias in any of the trials.
Effects of interventions
See: Summary of findings for the main comparison; Summary
of findings 2
Table 2 gives details regarding the number of individuals (with
IPD) contributing to each analysis, Summary of findings for the
main comparison summarises the results for the primary outcome
‘time to treatment withdrawal’ (stratified by epilepsy type) and
Summary of findings 2 summarises the results for the secondary
outcomes ‘time to first seizure’ and ‘time to 12-month remission.’
Figure 3, Figure 4, Figure 5; Figure 6; Figure 7; Figure 8; Figure
9 and Figure 10 show survival curve plots (cumulative incidence).
We produced all cumulative incidence plots in Stata software ver-
sion 14.1 (Stata 2015) using data from all trials providing IPD
combined.Wewould have liked to stratify by trial in survival curve
plots, but we do not know of any software that allows for this;
we hope that such software may have been developed for future
updates of this review. We note that participants with event times
of zero (i.e. those who withdrew from treatment or experienced
seizure recurrence on the day of randomisation) are not included
on the ‘numbers at risk’ on the graphs. All figures are intended to
provide a visual representation of outcomes, extent of follow-up
and visual differences between seizure types, and are not intended
to demonstrate statistical differences.
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Figure 3. Time to treatment withdrawal (tTime to withdrawal of allocated treatment)
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Figure 4. Time to treatment withdrawal (time to withdrawal of allocated treatment (by epilepsy type))
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Figure 5. Time to first seizure
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Figure 6. Time to first seizure (by epilepsy type)
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Figure 7. Time to 12-month remission
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Figure 8. Time to 12-month remission (by epilepsy type)
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Figure 9. Time to 6-month remission
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Figure 10. Time to 6-month remission (by epilepsy type)
We calculated all the HRs presented using generic inverse variance
fixed-effect meta-analysis unless otherwise stated. All analyses met
the assumption of proportional hazards (addition of time varying
covariate into the model non-significant) unless stated.
Primary Outcome
Time to withdrawal of allocated treatment
For this outcome, a HR less than 1 indicates a clinical advantage
for topiramate.
Table 3 shows the reasons for premature termination for 1151 par-
ticipants in the two trials included in this analysis and howwe clas-
sified these withdrawals in analysis of IPD. Times to withdrawal
of allocated treatment were available for 1129 participants in the
two trials (98% of total 1151 participants included in analysis).
Withdrawal times were missing for 22 participants in SANAD A
2007 (see Table 2); however, as all 22 participants withdrew for
reasons which would have been censored in analysis, we consider
the impact of these missing participants on the analysis to be neg-
ligible.
Of 1151 participants, 670 (58%) prematurely withdrew from
treatment: 377 of 644 (59%) participants randomised to topira-
mate and 293 of 507 (58%) participants randomised to carba-
mazepine.Wedeemed553participants (83%of total withdrawals)
to have withdrawn for reasons related to the allocated drug - 322
(85% of topiramate withdrawals) randomised to topiramate and
231 (79% of carbamazepine withdrawals) randomised to carba-
mazepine - and classified these withdrawals as ’events’ in analysis.
The most common treatment-related reason for withdrawal was
adverse events: 295 withdrawals (44% of total withdrawals), 159
(42% of total topiramate withdrawals) participants randomised
to topiramate and 136 (46% of total carbamazepine withdrawals)
participants randomised to carbamazepine.
We classed the other 117 withdrawals (55 participants randomised
to topiramate and 62 randomised to carbamazepine) to be not
related to the allocated drug and censored these participants in
analysis, in addition to the 481 participants (267 receiving topira-
mate and 214 receiving carbamazepine) who completed the trial
without withdrawing.
The overall pooledHR (for 1129 participants providing IPD from
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two trials) was 1.15 (95% CI 0.97 to 1.37, P = 0.10) indicating an
advantage to carbamazepine that was not statistically significant
(Analysis 1.1). No heterogeneity was present between trials (I2 =
0%).
Subgroup analyses: seizure type (partial-onset vs generalised-onset
or unclassified epilepsy)
See Subgroup analysis and investigation of heterogeneity for more
details regarding the definitions of subgroups.
For participants with generalised-onset or unclassified epilepsy
(155 participants providing IPD), the pooled HR was 0.90 (95%
CI 0.54 to 1.47, P = 0.66), indicating a slight advantage to top-
iramate that was not statistically significant, and for participants
with partial-onset seizures (974 participants providing IPD), the
pooledHR was 1.20 (95%CI 1.00 to 1.45, P = 0.05), indicating a
statistically significant advantage for carbamazepine. There was no
evidence of a difference between the subgroups (test for subgroup
differences P = 0.27, Analysis 1.2).
The overall pooled HR (adjusted for epilepsy type for 1129 par-
ticipants) was HR 1.16 (95% CI 0.98 to 1.38, P = 0.09), also
indicating an advantage to carbamazepine that is not statistically
significant. No between-trial heterogeneity was present overall or
by subgroup (I2 = 0%).
Sensitivity analysis
We performed a sensitivity analysis including only IPD from only
the 6-month double-blind period of Privitera 2003; participants
who withdrew from treatment after 6 months (9 receiving carba-
mazepine and 30 receiving topiramate) were censored at 6months.
When only withdrawals from the first 6 months of Privitera 2003
were combined with IPD from SANAD A 2007, numerical re-
sults were very similar and conclusions were unchanged (results
available from authors on request).
One included trial allocated participants to three treatment arms,
100mg/day topiramate, 200mg/day topiramate or carbamazepine
(Privitera 2003). Table 4 shows sensitivity analysis comparing the
primary analysis (pooled topiramate arms versus carbamazepine),
topiramate 100 mg/day versus carbamazepine and topiramate 200
mg/day versus carbamazepine. Results were similar across all three
analyses and conclusions were unchanged.
The reason for withdrawal ’participant choice’ was classified as an
event in this review but censored in the included trial (SANAD
A 2007). This was the primary reason for withdrawal specified in
14 participants (see Table 3). Sensitivity analysis classifying this
reason as a censored observation for these 14 participants did not
change our conclusions (results available from authors on request).
Secondary outcomes
Time to first seizure post randomisation
For this outcome, a HR less than 1 indicates a clinical advantage
for topiramate.
No seizure recurrence data after randomisation were available for
36 participants in SANAD A 2007, therefore 1115 participants
(97% of total 1151 participants) from the two trials were included
in the analysis of time to first seizure after randomisation.
A total of 720 participants (65% of participants included in anal-
ysis) experienced seizure recurrence, 403 of 624 (65%) receiving
topiramate and 317 of 491 (65%) receiving carbamazepine.
The overall pooledHR (for 1115 participants providing IPD from
two trials) was 1.09 (95%CI 0.94 to 1.27, P = 0.24), indicating an
advantage for carbamazepine that was not statistically significant
(Analysis 1.3). No important heterogeneity was present between
trials (I2 = 39%).
Subgroup analyses: seizure type (partial-onset vs generalised-onset
or unclassified epilepsy)
See Subgroup analysis and investigation of heterogeneity for more
details regarding the definitions of subgroups.
For participants with generalised-onset or unclassified epilepsy
(153 participants providing IPD), the pooled HR was 1.07 (95%
CI 0.69 to 1.67, P = 0.77) and for participants with partial-on-
set seizures (962 participants providing IPD), the pooled HR was
1.12 (95% CI 0.96 to 1.31, P = 0.16), both indicating an advan-
tage to carbamazepine that was not statistically significant. There
was no evidence of a difference between the subgroups (test for
subgroup differences P = 0.85, Analysis 1.4). There was some het-
erogeneity between the two trials in the subgroup of generalised-
onset or unclassified epilepsy (I2 = 63%), which is likely due to the
variability in the ’unclassifiable’ nature of the epilepsy in many of
the participants in this subgroup (i.e. the subgroup is likely to be
comprised of some individuals experiencing partial epilepsy and
others experiencing generalised epilepsy). No heterogeneity was
present in the subgroup of participants classified as having partial
epilepsy (I2 = 0%).
The overall pooled HR (adjusted for epilepsy type for 1115 par-
ticipants) was HR 1.11 (95% CI 0.96 to 1.29, P = 0.16), indi-
cating an advantage for carbamazepine that was not statistically
significant.
Sensitivity analysis
We performed a sensitivity analysis including only IPD from the
6-month double-blind period of Privitera 2003; participants who
experienced a first seizure recurrence after 6 months (8 receiving
carbamazepine and 11 receiving topiramate) were censored at 6
months. When only seizure recurrences from the first 6 months of
Privitera 2003 were combined with IPD from SANAD A 2007,
the numerical results were very similar and our conclusions were
unchanged (results available from authors on request).
One included trial allocated participants to three treatment arms,
100mg/day topiramate, 200mg/day topiramate or carbamazepine
(Privitera 2003). Table 4 shows sensitivity analysis comparing the
primary analysis (pooled topiramate arms versus carbamazepine),
topiramate 100 mg/day versus carbamazepine and topiramate 200
mg/day versus carbamazepine. Results were similar across all three
analyses and conclusions were unchanged.
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Time to 12-month remission of seizures
For this outcome, a HR less than 1 indicates a clinical advantage
for carbamazepine.
No seizure recurrence data after randomisation were available for
36 participants in SANAD A 2007, therefore 1115 participants
(97% of total 1151 participants) from the two trials were included
in the analysis of time to 12-month remission.
A total of 558 participants (50% of participants included in anal-
ysis) achieved 12-month remission; 277 of 624 (44%) receiving
topiramate and 281 of 491 (57%) receiving carbamazepine.
Of these 558 participants, 301 achieved immediate remission (i.e.
no seizure recurrence in the immediate 12 months following ran-
domisation) (54% of participants achieving remission), 151 re-
ceiving topiramate and 150 receiving carbamazepine.
The overall pooledHR (for 1115 participants providing IPD from
two trials) was 0.85 (95%CI 0.72 to 1.01, P = 0.07), indicating an
advantage for carbamazepine that was not statistically significant
(Analysis 1.5). No heterogeneity was present between trials (I2 =
0%).
Subgroup analyses: seizure type (partial-onset vs generalised-onset
or unclassified epilepsy)
See Subgroup analysis and investigation of heterogeneity for more
details regarding the definition of subgroups.
For participants with generalised-onset or unclassified epilepsy
(153 participants providing IPD), the pooled HR was 0.91 (95%
CI 0.58 to 1.43, P = 0.67), indicating an advantage for carba-
mazepine that was not statistically significant, and for participants
with partial-onset seizures (962 participants providing IPD), the
pooled HR was 0.84 (95% CI 0.71 to 1.00, P = 0.05), indicat-
ing a statistically significant advantage for carbamazepine. There
was no evidence of a difference between the subgroups (test for
subgroup differences P = 0.73, Analysis 1.6). There was some het-
erogeneity between the two trials in the subgroup of generalised-
onset or unclassified epilepsy (I2 = 62%), which is likely due to the
variability in the ’unclassifiable’ nature of the epilepsy in many of
the participants in this subgroup (i.e. the subgroup is likely to be
comprised of some individuals experiencing partial epilepsy and
others experiencing generalised epilepsy). No heterogeneity was
present in the subgroup of participants classified as having partial
epilepsy (I2 = 0%).
The overall pooledHR (adjusted for epilepsy type for 1115 partic-
ipants) was HR 0.84 (95% CI 0.71 to 1.00, P = 0.05), indicating
a statistically significant advantage for carbamazepine.
Sensitivity analysis
One included trial allocated participants to three treatment arms,
100mg/day topiramate, 200mg/day topiramate or carbamazepine
(Privitera 2003). Table 4 shows sensitivity analysis comparing the
primary analysis (pooled topiramate arms versus carbamazepine),
topiramate 100 mg/day versus carbamazepine and topiramate 200
mg/day versus carbamazepine. Results were similar across all three
analyses and conclusions were unchanged.
Time to 6-month remission of seizures
For this outcome, a HR less than 1 indicates a clinical advantage
for carbamazepine.
No seizure recurrence data after randomisation were available for
36 participants in SANAD A 2007, therefore 1115 participants
(97% of total 1151 participants) from the two trials were included
in the analysis of time to 6-month remission.
A total of 790 participants (71% of participants included in anal-
ysis) achieved 6-month remission; 422 of 624 (68%) receiving
topiramate and 368 of 491 (75%) receiving carbamazepine.
Of these 790 participants, 441 achieved immediate remission
(56% of participants achieving remission), 240 receiving topira-
mate and 201 receiving carbamazepine.
The overall pooledHR (for 1115 participants providing IPD from
two trials) was 0.88 (95%CI 0.77 to 1.02, P = 0.09), indicating an
advantage to carbamazepine that was not statistically significant
(Analysis 1.7). No heterogeneity was present between trials (I2 =
0%).
Subgroup analyses: seizure type (partial-onset vs generalised-onset
or unclassified epilepsy)
See Subgroup analysis and investigation of heterogeneity for more
details regarding the definitions of subgroups.
For participants with generalised-onset or unclassified epilepsy
(153 participants providing IPD), the pooled HR was 0.98 (95%
CI 0.67 to 1.44, P = 0.91) and for participants with partial-on-
set seizures (962 participants providing IPD), the pooled HR was
0.86 (95% CI 0.74 to 1.01, P = 0.06), both indicating an advan-
tage for carbamazepine that was not statistically significant. There
was no evidence of a difference between the subgroups (test for
subgroup differences P = 0.56, Analysis 1.8). There was some het-
erogeneity between the two trials in the subgroup of generalised-
onset or unclassified epilepsy (I2 = 67%), which is likely due to the
variability in the ’unclassifiable’ nature of the epilepsy in many of
the participants in this subgroup (i.e. the subgroup is likely to be
comprised of some individuals experiencing partial epilepsy and
others experiencing generalised epilepsy). No heterogeneity was
present in the subgroup of participants classified as having partial
epilepsy (I2 = 0%).
The overall pooled HR (adjusted for epilepsy type for 1115 par-
ticipants) was HR 0.88 (95% CI 0.76 to 1.01, P = 0.08), indi-
cating an advantage for carbamazepine that was not statistically
significant.
Sensitivity analysis
We performed a sensitivity analysis including only IPD from the 6-
month double-blind period of Privitera 2003; those who achieved
6months of remission after 6months (i.e. those who did not expe-
rience immediate 6-month remission, 11 receiving carbamazepine
and 41 receiving topiramate) were censored at 6 months. When
only immediate 6-month remission data from Privitera 2003 were
combined with IPD from SANAD A 2007, the pooled HR was
0.86 (0.75 to 1.00, P = 0.05), indicating a statistically significant
advantage for carbamazepine over topiramate. We note that this
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analysis combines immediate 6-month remission in Privitera 2003
with 6-month remission at any time in SANAD A 2007. When
analysing only immediate 6-month remission in SANADA 2007,
the pooled HR was 0.88 (0.73 to 1.07, P = 0.19) indicating no
significant difference between the drugs.
One included trial allocated participants to three treatment arms,
100mg/day topiramate, 200mg/day topiramate or carbamazepine
(Privitera 2003). Table 4 shows sensitivity analysis comparing the
primary analysis (pooled topiramate arms versus carbamazepine),
topiramate 100 mg/day versus carbamazepine and topiramate 200
mg/day versus carbamazepine. Results were similar across all three
analyses and conclusions were unchanged.
Incidence of adverse events
Wewere provided with IPD for adverse events experienced during
the trial for two trials (Privitera 2003; SANAD A 2007).
Due to the wide range of events reported in the trials and the
differences in adverse-event profiles of the two drugs, we have
not analysed adverse event data in meta-analysis and provide a
narrative report. This information is summarised in Table 5 and
Table 6. All adverse events are reported according to the definitions
within the data provided to us.
The five most commonly reported adverse events with the two
drugs were drowsiness or fatigue, ‘pins and needles’ (tingling sen-
sation), headache, gastrointestinal disturbance and anxiety or de-
pression. Rash and dizziness (feeling faint) were also commonly re-
ported with carbamazepine, and anorexia or weight loss was com-
monly reported with topiramate.
In Privitera 2003, 58 serious adverse events were reported in 29
individuals.
With topiramate 100 mg, there were 12 serious adverse events in
10 participants. One event of renal calculus in one participant,
and one event of grand mal convulsions in one participant, were
possibly related to treatment. All other events were unlikely to be
related to treatment: two events of grand mal convulsions in two
participants; and one event of ’regression’, one event of hypoten-
sion, one event of thrombophlebitis, one event of worsened con-
vulsions, one event of abnormal hepatic function, one event of
oedema, one event of asthenia and one event of aggravated depres-
sion (resulting in withdrawal of the drug) all in one participant
each.
With topiramate 200 mg, there were 29 serious adverse events in
11 participants. One event of renal calculus was very likely to be
related to the treatment and another event of renal calculus was
probably related to treatment. Nine events of confusion and ag-
gravated depression in one participant were also probably related
to treatment. The drug was withdrawn from these three partici-
pants. All other events were unlikely to be related to treatment:
two events of adenocarcinoma in one participant; three events of
dizziness, nausea and palpitations in one participant; eight events
of headache, back pain, confusion, fever and upper respiratory
tract infection in one participant; and one injury, one event of
asthma, one event of migraine, one event of ileus, one event of
chest pain and one event of foetal death all in one participant each.
None of the unrelated adverse events resulted in withdrawal of the
drug.
On carbamazepine, there were 17 serious adverse events in 8 par-
ticipants. One event of grand mal convulsions was very likely to
be related to the treatment. All other events were unlikely to be
related to treatment: seven events of diverticulitis and hyperten-
sion in one participant; two events of enteritis in one participant;
three events of dyspnoea and chest pain in one participant; and
one event of syncope, one abscess, one injury and one case of ab-
dominal pain all in one participant each. None of these events
resulted in withdrawal of treatments.
In SANAD A 2007, 179 events resulting in hospitalisation were
reported in 101 participants (not stated whether events were re-
lated to treatment).
On topiramate, there were 88 hospitalisation events in 55 par-
ticipants: 21 events of worsening seizures or status epilepticus in
13 participants (resulting in withdrawal of the drug in two par-
ticipants); accidental injuries in four participants; six events of
headache in three participants (resulting in withdrawal of the drug
in one participant); accidental drug overdoses in three participants;
brain tumours in three participants (resulting in withdrawal of the
drug in one participant); abdominal pain in three participants (re-
sulting in withdrawal of the drug in one participant); three coro-
nary artery bypass grafts in two participants; chest pain in two
participants; renal malignancy in two participants; depression in
two participants; visual disturbances in two participants (resulting
in withdrawal of the drug in one participant); self harm/suicide
attempt in two participants (resulting in withdrawal of the drug
in one participant); urinary tract infections in two participants;
thrombosis in two participants; three events of ataxia in one par-
ticipant; three events of Crohn’s Disease in one participant; two
events of dizziness in one participant; and one cataract operation,
one event of hypertension, one event of sarcoidosis, one testicu-
lar lump, one event of urinary incontinence, one miscarriage, one
event of henoch schonlein purpura, one event of Steven Johnsons
syndrome (resulting in withdrawal of the drug), and one collapsed
lung all in one participant each.
On carbamazepine, there were 91 hospitalisation events in 46 par-
ticipants: worsening of seizures in 12 participants; cardiovascular
events in five participants; attempted suicide in three participants;
seizure-related injury in three participants; allergic rash in two
participants; pneumonia in two participants; and antiphospho-
lipid syndrome, arthritis, stomach cancer, urinary tract infection,
disorientation, psychotic illness (resulting in withdrawal of the
drug), exacerbation of chronic obstructive pulmonary disease, hys-
terectomy (resulting in withdrawal of the drug), torsion of testis,
myringotomy, infection, worsening of seizures and visual distur-
bance (resulting in withdrawal of the drug), constipation (result-
ing in withdrawal of the drug), low serum, breast cancer, abdom-
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inal pain, ataxia, childbirth, and headache all in one participant
each.
Summary of aggregate results reported in Resendiz-
Aparicio 2004
IPD were not available for the 88 participants randomised in
Resendiz-Aparicio 2004.
Forty-six participants were randomised to topiramate and 42 were
randomised to carbamazepine; 23 participants dropped out due to
adverse events, lack of efficacy or loss to follow-up (13 randomised
to topiramate and 10 randomised to carbamazepine). Results were
presented only for the 33 participants randomised to topiramate
and 32 randomised to carbamazepine who did not drop out of the
study.
Thirty participants on topiramate and 26 on carbamazepine
achieved 6 months of freedom from seizures after 12 months of
treatment and 32 participants receiving topiramate and 27 receiv-
ing carbamazepine achieved a 50% or more reduction in seizures
during the same time frame. The average number of seizures was
significantly lower in the topiramate group than in the carba-
mazepine group at 6 and 9 months (P value of t-test = 0.01).
No clinically significant changes were observed in clinical or phys-
ical examinations in either group. Adverse event experiences were
mild and similar between groups: somnolence (in three receiving
topiramate and six receiving carbamazepine); dizziness (one re-
ceiving topiramate and two receiving carbamazepine); weight loss
or anorexia (five receiving topiramate); gastritis (one receiving top-
iramate); nausea (one receiving topiramate); rash (one receiving
carbamazepine); headache (one receiving carbamazepine); uncon-
trolled seizures (one receiving carbamazepine).
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A D D I T I O N A L S U M M A R Y O F F I N D I N G S [Explanation]
Topiramate compared with carbamazepine for epilepsy
Population: Adults and children with epilepsy
Settings: Outpat ients
Intervention: Topiramate
Comparison: Carbamazepine
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
No. of participants
(studies)
Quality of the evidence
(GRADE)
Comments
Assumed risk Corresponding risk
Carbamazepine Topiramate
Time to first seizure
after randomisation -
stratified by epilepsy
type
Range of follow up: 0 to
2420 days
646 per 1000 684 per 1000
(631 to 738)
HR: 1.11
(0.96 to 1.29)
1129
(2 studies)
⊕⊕⊕⊕
high
HR > 1 indicates a clin-
ical advantage for topi-
ramate
Time to first seizure
after randomisation -
stratified by epilepsy
type - partial onset
Range of follow up: 0 to
2420 days
660 per 1000 702 per 1000
(645 to 756)
HR: 1.12
(0.96 to 1.31)
962
(2 studies)
⊕⊕⊕⊕
high
HR > 1 indicates a clin-
ical advantage for topi-
ramate
Time to first seizure
after randomisation -
stratified by epilepsy
type - generalised-
onset or unclassified
epilepsy
Range of follow up: 0 to
853 days
542 per 1000 567 per 1000
(417 to 729)
HR: 1.07
(0.69 to 1.67)
153
(2 studies)
⊕⊕⊕©
moderate1
HR > 1 indicates a clin-
ical advantage for topi-
ramate
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Time to 12-month re-
mission of seizures -
stratified by epilepsy
type
Range of follow up: 0 to
2420 days
572 per 1000 510 per 1000
(453 to 572)
HR: 0.84
(0.71 to 1.00)
1129
(2 studies)
⊕⊕⊕⊕
high
HR > 1 indicates a clin-
ical advantage for car-
bamazepine
Time to 12-month re-
mission of seizures -
stratified by epilepsy
type - partial onset
Range of follow up: 0 to
2420 days
574 per 1000 508 per 1000
(445 to 574)
HR: 0.83
(0.69 to 1.00)
962
(2 studies)
⊕⊕⊕⊕
high
HR > 1 indicates a clin-
ical advantage for car-
bamazepine
Time to 12-month re-
mission of seizures -
stratified by epilepsy
type - generalised-
onset or unclassified
epilepsy
Range of follow up: 0 to
853 days
559 per 1000 526 per 1000
(378 to 690)
HR: 0.91
(0.58 to 1.43)
153
(2 studies)
⊕⊕⊕©
moderate1
HR > 1 indicates a clin-
ical advantage for car-
bamazepine
The assumed risk is calculated as the event rate in the carbamazepine treatment. The corresponding risk (and its 95% CI) is based on the assumed risk in the comparison
group and the relative effect of the intervent ion (and its 95% CI).
The corresponding risk is calculated as the assumed risk x the relat ive risk (RR) of the intervent ion where RR = (1 - exp(HR x ln(1 - assumed risk)))/ assumed risk.
CI: Conf idence interval; HR: Hazard Ratio;
GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our conf idence in the est imate of ef fect.
M oderate quality: Further research is likely to have an important impact on our conf idence in the est imate of ef fect and may change the est imate.
Low quality: Further research is very likely to have an important impact on our conf idence in the est imate of ef fect and is likely to change the est imate.
Very low quality: We are very uncertain about the est imate.
1. Downgraded once for imprecision and applicability, lim ited information on generalised seizure types and most part icipants
do not have a classif ied seizure type in this subgroup so the interpretat ion of this seizure type is unclear.
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D I S C U S S I O N
Summary of main results
IPD were available for two trials recruiting 1151 participants to
carbamazepine or topiramate (Privitera 2003; SANAD A 2007).
For the third trial, which recruited 88 participants, the original
authors could not be contacted, so IPD could not be included in
this review (Resendiz-Aparicio 2004). Overall, IPD were available
for 93% of the total eligible 1239 participants.
The results of this review showno statistically significant difference
between topiramate and carbamazepine for our primary global ef-
ficacy outcome ’time to withdrawal of allocated treatment’ (pooled
HR 1.16, 95% CI 0.98 to 1.38, P = 0.09) for participants with
partial-onset seizures and generalised tonic-clonic seizures with or
without other seizure types and unclassified seizure types. Con-
sidering only individuals with partial-onset seizures (85% of par-
ticipants contributing to the analysis), an advantage for carba-
mazepinewas observed for our primary outcome (pooledHR1.20,
95%CI 1.00 to 1.45, P = 0.05). This advantage was not shown for
individuals with generalised tonic-clonic seizures with or without
other seizure types and unclassified seizure types (pooledHR 0.90,
95% CI 0.54 to 1.47, P = 0.66). Results were unchanged when
we used definitions of treatment withdrawal that differed from the
definition used in this review (ILAE 1998).
The results of this review also show no statistically significant dif-
ference between topiramate and carbamazepine for our secondary
outcomes of ’time to first seizure’ and ’time to 6-month remis-
sion’ for individuals with all eligible seizure types. For ’time to
12-month remission,’when adjusted for seizure type (partial-onset
compared with generalised-onset or unclassified seizures), a signif-
icant advantage was shown for carbamazepine (pooled HR 0.84,
95%CI 0.71 to 1.00, P = 0.05). Considering partial-onset seizures
only, an advantage for carbamazepine was also found for ’time to
12-month remission’ (pooled HR 0.83, 95% CI 0.69 to 1.00, P
= 0.05), but no differences were found within other seizure-type
subgroups for these outcomes. We note that some of the pooled
results from the two studies included in this review approached
but did not reach statistical significance; hence, we cannot rule
out that important differences may exist between the drugs which
may come to light if more evidence can be incorporated into the
review in future updates.
The five most commonly reported adverse events with the two
drugs were drowsiness or fatigue, ‘pins and needles’ (tingling sen-
sation), headache, gastrointestinal disturbance and anxiety or de-
pression. Rash and dizziness (feeling faint) were also commonly re-
ported with carbamazepine, and anorexia or weight loss was com-
monly reported with topiramate. The rates of adverse events and
serious adverse events were similar across the two drugs.
Overall completeness and applicability of
evidence
We believe our systematic electronic searches identified all relevant
evidence for this review. We gratefully received IPD for 1151 indi-
viduals (93% of 1239 individuals from all eligible trials) from the
authors or sponsors of two trials (Privitera 2003; SANADA 2007)
that included a comparison of topiramate with carbamazepine for
the treatment of epilepsy.
At the time the
review was conducted, we were unable to obtain IPD for the re-
maining trial (Resendiz-Aparicio 2004), which randomised a total
of 88 participants. We were not able to make contact with a study
author. If IPD are received from this trial, we will include them in
future review updates. We do not believe that our failure to obtain
IPD from 7% of eligible participants from this single trial has had
a large impact on the applicability of the results of the review.
Eligible seizure types included in this review were partial-onset
and generalised tonic-clonic (without or without other generalised
types). Due to the design of the two studies contributing to analy-
sis, amajority of participants recruited into these trials experienced
partial-onset seizures (85% of randomised participants) and most
of the remaining participants had an unclassified seizure type.
As a result, the results of this review are primarily applicable to
participants with partial-onset seizures and we encourage caution
in the interpretation of results for the small subgroup of partici-
pants who had generalised-onset or unclassified epilepsy.
Quality of the evidence
The two trials for which IPD were made available (as well as
additional trial design information from trial authors/sponsors)
were generally of good quality. One of the trials was double-blind
(Privitera 2003) and one was open-label (SANADA 2007).While
it is argued that an open-label design is more pragmatic and re-
flective of the ’real world’ treatment of a chronic condition such as
epilepsy where treatments are likely to be taken long term by par-
ticipants (SANAD A 2007), significantly more participants with-
drew from treatment in the open-label study than in the double-
blind study (51% vs 44%, Chi2 P = 0.03). Both of the trials con-
tributing to analysis in this review compared a ’new’ intervention
with a ’standard’ intervention, and knowledge of the treatment
allocation may have influenced the choice of the participant or
clinician to continue taking the treatment. This, in turn, may have
influenced the perceived effectiveness of the two drugs under com-
parison. We have, therefore, considered an open-label design to
potentially introduce bias into the results for the subjective out-
come of time to treatment withdrawal, but not for the objective
secondary outcomes of time to first seizure and remission.
Due to the potential risk of bias from an open-label design, we have
rated the evidence provided in this review, according to GRADE
criteria, for our primary outcome of time to treatment withdrawal
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as ‘moderate’ for all participants and the subgroup of participants
with partial-onset seizures. Due to the limited number of partic-
ipants with generalised-onset seizures (and, hence, the potential
misclassification of seizure type), we have rated this evidence as
low quality for the primary outcome, see Summary of findings
for the main comparison. For our secondary (objective) outcomes
of time to first seizure and remission, we have rated evidence as
high quality (moderate quality in the subgroup of participants
with generalised-onset seizures for the reasons stated above) (see
Summary of findings 2).
Potential biases in the review process
We were able to include IPD for 1151 of 1239 eligible partici-
pants (93%) from two of three trials in this review and were able
to analyse all outcomes using IPD. Such an approach has many
advantages, such as allowing the standardisation of definitions of
outcomes across trials. In addition, attrition and reporting biases
are reduced as we can perform additional analyses and calculate
additional outcomes from unpublished data. For the outcomes we
used in this review that are of a time-to-event nature, an IPD ap-
proach is considered to be the ’gold standard’ approach to analysis
(Parmar 1998).
For reasons outside of our control, we were unable to obtain IPD
for 88 participants from one trial for inclusion in this review.
However, we do not believe that the exclusion of 7% of eligible
participants is likely to have impacted on the conclusions of this
review (see Overall completeness and applicability of evidence).
Finally, we made some assumptions in the statistical methodology
used in this review. First, when we received only follow-up dates
and seizure frequencies from the authors of the included studies,
we used linear interpolation to estimate approximate seizure dates.
We are aware that an individual’s seizure patterns may be non-
linear; therefore, we recommend caution when interpreting the
numerical results of the seizure-related outcomes.
We also made an assumption that treatment effect for each out-
come did not change over time (proportional hazards assumption,
see Data synthesis). We are aware that in trials of long duration
(e.g. SANAD A 2007, which was of over one year in duration),
the assumption that treatment effect remains constant over time
is unlikely to be appropriate; for example, there is likely to be a
difference between participants who achieve immediate remission
compared with participants who achieve later remission. There-
fore, if future updates of this review include more trials of long
duration, we would like to perform statistical analyses that allow
for treatment effects to vary over time.
Agreements and disagreements with other
studies or reviews
To our knowledge, this is the only systematic review and meta-
analysis that compares topiramate and carbamazepine monother-
apy for partial-onset seizures and generalised-onset tonic-clonic
seizures. A network meta-analysis has been published (Tudur
Smith 2007), comparing all direct and indirect evidence from top-
iramate, carbamazepine, and other standard and new AEDs li-
censed for monotherapy. The results of this review generally agree
with the results of this network meta-analysis. The network meta-
analysis is currently being updated to include more recently pub-
lished trials and will include the results of Privitera 2003; when
available, we will compare the results of this review with the up-
dated network meta-analysis.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
Current UK guidelines recommend carbamazepine or lamotrig-
ine as first-line treatment for adults and children with new-on-
set partial seizures, and sodium valproate for adults and children
with new-onset generalised seizures. Topiramate is not currently
recommended as a first- or second-line treatment for use in new-
onset partial or generalised seizures (NICE 2012). The results of
this review do not provide any conclusive evidence for or against
these guidelines.
There is some suggestion from the results of this review that carba-
mazepine may be a more effective drug for individuals with new-
onset partial seizures in terms of treatment retention (withdrawals
due to lack of efficacy, or adverse events, or both occurred later
with carbamazepine) and that these individuals may achieve a year
of remission from seizures earlier with carbamazepine than with
topiramate. However, this difference was not observed for recur-
rence of a first seizure and for remission of a shorter period.
For individuals with new-onset generalised tonic-clonic seizures
with or without other generalised seizure types, the evidence in
the review is limited due to the small numbers of participants with
generalised seizure types recruited into the included trials. Fur-
thermore, an important proportion of individuals had unclassified
seizure types, and evidence is limited and inconclusive for these
participants.
There is evidence that carbamazepine may exacerbate some gen-
eralised seizure types, and so should be used with caution in indi-
viduals with this seizure type (Liporace 1994; Shields 1983; Snead
1985). Topiramate may be an effective alternative treatment op-
tion to sodium valproate for new-onset generalised seizures, but
more evidence is required to confirm this (NICE 2012). Newer
antiepileptic drugs, such as topiramate, may be associated with less
intolerable side effects than older drugs, such as carbamazepine
(French 2007); however, the results of the review do not suggest
that topiramate is better- or worse-tolerated than carbamazepine.
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Implications for research
Results of this review are taken from the synthesis of 1151 of 1239
eligible participants from two of three eligible trials. Some of the
pooled results from the two studies included in this review ap-
proached but did not reach statistical significance; we therefore
do not rule out that important differences may exist between the
drugs which may come to light if more evidence can be incorpo-
rated into the review during future updates.
This review highlights the need for the design of future antiepilep-
tic drug monotherapy trials that recruit individuals with specific
epilepsy syndromes to be powered to detect a difference between
particular antiepileptic drugs. An approach likely to reflect and in-
form clinical practice, as well as being statistically powerful, would
be to recruit heterogeneous populations for whom epilepsy syn-
dromes have been adequately defined, with testing for interactions
between treatments and epilepsy syndromes.
In view of potential problems arising fromunclassified seizures and
the misclassification of seizure type, it is important that epilepsy
syndromes should be well defined in the inclusion criteria of fu-
ture trials, with adequate checking mechanisms to ensure that
classifications are accurate and a system to recognise uncertainty
surrounding epilepsy syndromes in individuals within trials. This
most commonly applies to tonic-clonic seizures that may be gen-
eralised at onset, or which may be secondarily generalised. In any
trial, such unclassified individuals need to be clearly identified,
because if they are not they may confound the interpretation of
the results for well-classified individuals. We need to know how to
manage participants whose classification we find more difficult.
It is also important that future trials are of a sufficient duration to
measure the long-term effectiveness of antiepileptic drugs - treat-
ments that will be life-long for many individuals with epilepsy - as
well as psychosocial, quality of life and health economic outcomes.
Consideration is also required in the design of a trial regarding
whether to blind participants and outcome assessors to treatment
allocation. While an open-label design is a more pragmatic and
practical approach for large long-term trials, when trials compare
a new intervention with an established ’standard’ intervention,
masking of treatment may be important to avoid preconceptions
over the relative effectiveness of the drugs.
The choice of outcomes at the design stage of a trial and the pre-
sentation of the results of outcomes, particularly of a time-to-event
nature, require very careful consideration. While the majority of
trials of a monotherapy design record an outcome measuring effi-
cacy (seizure control) and an outcome measuring tolerability (ad-
verse events), there is little uniformity between the definition of the
outcomes and the reporting of the summary statistics related to the
outcomes (Nolan 2013a), making an aggregate data approach to
meta-analysis in reviews of monotherapy trials impossible. Where
trial authors cannot or will not make individual participant data
available for analysis, we are left with no choice but to exclude a
proportion of relevant evidence from the review, which may im-
pact upon the interpretation of the results of the review and the
applicability of the evidence and conclusions. The International
League Against Epilepsy recommends that trials of a monother-
apy design should adopt a primary effectiveness outcome of ’time
to withdrawal of allocated treatment (retention time)’ and should
be of a duration of at least 48 weeks to allow for the assessment
of longer-term outcomes such as remission (ILAE 1998; ILAE
2006). If trials followed these recommendations, an aggregate data
approach tometa-analysis could be feasible, reducing the resources
and time required by an individual participant data approach.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Privitera 2003
Methods Multinational, randomised, double-blind trial conducted at 115 centres across the USA,
Canada, Europe and South America
Four treatments: CBZ, SV and TPM (two arms, 100 mg/day and 200 mg/day) (see
Notes)
Participants Participants over the age of 6 years and over 30 kg in weight, with a diagnosis of epilepsy
within the three months before trial entry and no previous AED treatment except emer-
gency treatment
Number randomised (ITT population): CBZ = 126, TPM = 264 (CBZ branch)
215 male participants (54%)
322 participants with partial epilepsy (82%)
Mean age (range): 34 (6 to 80 years)
Interventions Monotherapy with CBZ or TPM
Starting doses: CBZ = 200 mg/day, TPM = 25 mg/day
Target doses (after 4 week titration): CBZ = 600 mg/day, TPM = 100 or 200 mg/day
(see Notes)
Range of follow up: 0 to 29 months
Outcomes Time to exit from the study
Time to first seizure
Proportionof seizure-free participants during the last 6months of double-blind treatment
Safety assessment: Most commonly occurring adverse events
Notes IPD provided for all outcomes of this review by trial sponsor Johnson & Johnson. Trial
designed in two strata based on whether recommended treatment would be CBZ or SV.
Within the two strata, participants were randomised to 100 mg/day TPM, 200 mg/day
TPM or CBZ/SV depending on the strata. Data analysed according to the separate strata
in this review with the two TPM doses analysed together; separate doses of TPM are
considered in sensitivity analysis (see Data extraction and management)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Randomisation was balanced using per-
muted blocks of size three and stratified by
trial centre, according to a computer-gen-
erated randomisation schedule prepared by
the trial sponsor
Allocation concealment (selection bias) Unclear risk No information provided
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Privitera 2003 (Continued)
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Trial was double-blinded for the first 6
months, followed by an open-label phase
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk No information provided
Incomplete outcome data (attrition bias)
All outcomes
Low risk Attrition rates reported, ITT approach,
all randomised participants from the ITT
population analysed from IPD provided
(see footnote 2). Eight participants with
no follow-up data were excluded from ITT
population
Selective reporting (reporting bias) Low risk All outcomes reported or calculated with
IPD provided (see footnote 2)
Other bias Low risk None identified
Resendiz-Aparicio 2004
Methods Randomised open label trial conducted in several hospitals in Mexico
Two treatment arms: CBZ and TPM
Participants Participants between2 and18yearswith newly diagnosed partial epilepsywith orwithout
secondary generalisation with at least two unprovoked seizures more than 24 hours apart
and at least one seizure in the last 6 months. Participants must have no established
treatment and have received no antiepileptic treatment within the past 30 days
Number randomised: CBZ = 42, TPM = 46. Number included in analysis CBZ = 32,
TPM = 33
100% partial epilepsy
33 male participants (60%) included in analysis
Mean age (range): CBZ = 10 (5 to 17) years, TPM = 8 (2 to 16) years for participants
included in analysis
Interventions Monotherapy with CBZ or TPM
Treatments titrated to a maximum of CBZ = 20 to 25 mg/kg/day, TPM = 9 mg/kg/day
Follow-up assessments at 6 and 9 months, range of follow-up not stated
Outcomes Seizure freedom and frequency of seizures during the trial
Adverse events during the trial
Laboratory results
Notes The trial was published in Spanish; the characteristics and outcomes were translated.
Outcomes chosen for this review were not reported; contact could not be made with
trial author to provide IPD
Results presented only for those who completed the trial. Those with less than 35%
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Resendiz-Aparicio 2004 (Continued)
reduction of seizures were excluded from analysis
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Random number tables used to assign par-
ticipants to treatment groups
Allocation concealment (selection bias) Unclear risk No information provided
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Open label trial
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Open label trial
Incomplete outcome data (attrition bias)
All outcomes
High risk Attrition rates reported (23 drops outs, 10
forCBZ and 13 for TPM).Only those who
completed the trial were included in analy-
sis (non responders to treatment excluded)
, this is not an ITT approach
Selective reporting (reporting bias) Low risk No protocol available. Seizure outcomes
and adverse events well reported
Other bias Low risk None identified
SANAD A 2007
Methods Randomised, multicentre, open-label, parallel-group trial conducted in the UK
Five treatment arms: LTG, CBZ, GBP, TPM and OXC
Participants Adults and children over the age of 4 years with newly diagnosed partial epilepsy, relapsed
partial epilepsy or failed treatment with a previous drug not used in this trial
Number randomised: CBZ = 378, TPM = 378
408 male participants (54%)
654 partial epilepsy (97%)
139 had received previous AED treatment (18%)
Mean age(range): 39 (5 to 86) years
Interventions Monotherapy for CBZ or TPM
Titration doses and maintenance doses decided by treating clinician
Range of follow up: 0 to 86 months
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SANAD A 2007 (Continued)
Outcomes Time to treatment failure
Time to 1 year (12 month) remission
Time to 2 year remission
Time to first seizure
Health-related quality of life via the NEWQOL (Newly Diagnosed Epilepsy Quality of
Life Battery)
Health economic assessment and cost effectiveness of the drugs (cost per QALY gained
and cost per seizure avoided)
Frequency of clinically important adverse events
Notes IPD provided for time to treatment withdrawal, time to first seizure, time to 6-month
remission, time to 12-month remission (trial coordinated at our site)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer minimisation programme strat-
ified by centre, sex and treatment history
Allocation concealment (selection bias) Low risk Telephone randomisation to a central ran-
domisation allocation service
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Open label trial
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Open label trial
Incomplete outcome data (attrition bias)
All outcomes
Low risk Attrition rates reported, all randomised
participants analysed from IPD provided
(see footnote 2)
Selective reporting (reporting bias) Low risk Protocol provided. All outcomes reported
or calculated with IPD provided (see foot-
note 2)
Other bias Low risk None identified
Abbreviations: AED: antiepileptic drug, CBZ: Carbamazepine; GBP: gabapentin, IPD: individual participant data, ITT: intention to
treat, LTG: lamotrigne, OXC: oxcarbazepine, QALY: quality-adjusted life-year, SV: sodium valproate, TPM: topirimate
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Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Kang 2007 Ineligible epilepsy type
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D A T A A N D A N A L Y S E S
Comparison 1. Topiramate monotherapy (TPM) versus Carbamazepine (CBZ) monotherapy
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Time to withdrawal of allocated
treatment
2 1129 Hazard Ratio (Fixed, 95% CI) 1.15 [0.97, 1.37]
2 Time to withdrawal of allocated
treatment - stratified by
epilepsy type
2 1129 Hazard Ratio (Fixed, 95% CI) 1.16 [0.98, 1.38]
2.1 Generalised Onset or
Unclassified Epilepsy
2 155 Hazard Ratio (Fixed, 95% CI) 0.90 [0.54, 1.47]
2.2 Partial Onset 2 974 Hazard Ratio (Fixed, 95% CI) 1.20 [1.00, 1.45]
3 Time to first seizure after
randomisation
2 1115 Hazard Ratio (Fixed, 95% CI) 1.09 [0.94, 1.27]
4 Time to first seizure after
randomisation - stratified by
epilepsy type
2 1115 Hazard Ratio (Fixed, 95% CI) 1.11 [0.96, 1.29]
4.1 Generalised Onset or
Unclassified Epilepsy
2 153 Hazard Ratio (Fixed, 95% CI) 1.07 [0.69, 1.67]
4.2 Partial Onset 2 962 Hazard Ratio (Fixed, 95% CI) 1.12 [0.96, 1.31]
5 Time to 12 month remission of
seizures
2 1115 Hazard Ratio (Fixed, 95% CI) 0.85 [0.72, 1.01]
6 Time to 12 month remission of
seizures - stratified by epilepsy
type
2 1115 Hazard Ratio (Fixed, 95% CI) 0.84 [0.71, 1.00]
6.1 Generalised Onset or
Unclassified Epilepsy
2 153 Hazard Ratio (Fixed, 95% CI) 0.91 [0.58, 1.43]
6.2 Partial Onset 2 962 Hazard Ratio (Fixed, 95% CI) 0.83 [0.69, 1.00]
7 Time to 6 month remission of
seizures
2 1115 Hazard Ratio (Fixed, 95% CI) 0.88 [0.77, 1.02]
8 Time to 6 month remission of
seizures - stratified by epilepsy
type
2 1115 Hazard Ratio (Fixed, 95% CI) 0.88 [0.76, 1.01]
8.1 Generalised Onset or
Unclassified Epilepsy
2 153 Hazard Ratio (Fixed, 95% CI) 0.98 [0.67, 1.44]
8.2 Partial Onset 2 962 Hazard Ratio (Fixed, 95% CI) 0.86 [0.74, 1.01]
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Analysis 1.1. Comparison 1 Topiramate monotherapy (TPM) versus Carbamazepine (CBZ) monotherapy,
Outcome 1 Time to withdrawal of allocated treatment.
Review: Topiramate versus carbamazepine monotherapy for epilepsy: an individual participant data review
Comparison: 1 Topiramate monotherapy (TPM) versus Carbamazepine (CBZ) monotherapy
Outcome: 1 Time to withdrawal of allocated treatment
Study or subgroup Topiramate (TPM)
Carbamazepine
(CBZ) log [Hazard Ratio] Hazard Ratio Weight Hazard Ratio
N N (SE) IV,Fixed,95% CI IV,Fixed,95% CI
Privitera 2003 266 129 0.03868 (0.16387) 28.7 % 1.04 [ 0.75, 1.43 ]
SANAD A 2007 366 368 0.18627 (0.10398) 71.3 % 1.20 [ 0.98, 1.48 ]
Total (95% CI) 632 497 100.0 % 1.15 [ 0.97, 1.37 ]
Heterogeneity: Chi2 = 0.58, df = 1 (P = 0.45); I2 =0.0%
Test for overall effect: Z = 1.64 (P = 0.10)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours Topiramate Favours Carbamazepine
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Analysis 1.2. Comparison 1 Topiramate monotherapy (TPM) versus Carbamazepine (CBZ) monotherapy,
Outcome 2 Time to withdrawal of allocated treatment - stratified by epilepsy type.
Review: Topiramate versus carbamazepine monotherapy for epilepsy: an individual participant data review
Comparison: 1 Topiramate monotherapy (TPM) versus Carbamazepine (CBZ) monotherapy
Outcome: 2 Time to withdrawal of allocated treatment - stratified by epilepsy type
Study or subgroup Topiramate (TPM)
Carbamazepine
(CBZ) log [Hazard Ratio] Hazard Ratio Weight Hazard Ratio
N N (SE) IV,Fixed,95% CI IV,Fixed,95% CI
1 Generalised Onset or Unclassified Epilepsy
Privitera 2003 48 25 -0.32533 (0.37335) 5.6 % 0.72 [ 0.35, 1.50 ]
SANAD A 2007 47 35 0.07497 (0.34629) 6.5 % 1.08 [ 0.55, 2.12 ]
Subtotal (95% CI) 95 60 12.0 % 0.90 [ 0.54, 1.47 ]
Heterogeneity: Chi2 = 0.62, df = 1 (P = 0.43); I2 =0.0%
Test for overall effect: Z = 0.43 (P = 0.66)
2 Partial Onset
Privitera 2003 218 104 0.12568 (0.18336) 23.0 % 1.13 [ 0.79, 1.62 ]
SANAD A 2007 319 333 0.20689 (0.10918) 65.0 % 1.23 [ 0.99, 1.52 ]
Subtotal (95% CI) 537 437 88.0 % 1.20 [ 1.00, 1.45 ]
Heterogeneity: Chi2 = 0.14, df = 1 (P = 0.70); I2 =0.0%
Test for overall effect: Z = 1.98 (P = 0.048)
Total (95% CI) 632 497 100.0 % 1.16 [ 0.98, 1.38 ]
Heterogeneity: Chi2 = 1.96, df = 3 (P = 0.58); I2 =0.0%
Test for overall effect: Z = 1.71 (P = 0.088)
Test for subgroup differences: Chi2 = 1.19, df = 1 (P = 0.27), I2 =16%
0.01 0.1 1 10 100
Favours Topiramate Favours Carbamazepine
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Analysis 1.3. Comparison 1 Topiramate monotherapy (TPM) versus Carbamazepine (CBZ) monotherapy,
Outcome 3 Time to first seizure after randomisation.
Review: Topiramate versus carbamazepine monotherapy for epilepsy: an individual participant data review
Comparison: 1 Topiramate monotherapy (TPM) versus Carbamazepine (CBZ) monotherapy
Outcome: 3 Time to first seizure after randomisation
Study or subgroup Topiramate (TPM)
Carbamazepine
(CBZ) log [Hazard Ratio] Hazard Ratio Weight Hazard Ratio
N N (SE) IV,Fixed,95% CI IV,Fixed,95% CI
Privitera 2003 266 129 0.2738 (0.16232) 22.2 % 1.31 [ 0.96, 1.81 ]
SANAD A 2007 358 362 0.03733 (0.08666) 77.8 % 1.04 [ 0.88, 1.23 ]
Total (95% CI) 624 491 100.0 % 1.09 [ 0.94, 1.27 ]
Heterogeneity: Chi2 = 1.65, df = 1 (P = 0.20); I2 =39%
Test for overall effect: Z = 1.17 (P = 0.24)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours Topiramate Favours Carbamazepine
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Analysis 1.4. Comparison 1 Topiramate monotherapy (TPM) versus Carbamazepine (CBZ) monotherapy,
Outcome 4 Time to first seizure after randomisation - stratified by epilepsy type.
Review: Topiramate versus carbamazepine monotherapy for epilepsy: an individual participant data review
Comparison: 1 Topiramate monotherapy (TPM) versus Carbamazepine (CBZ) monotherapy
Outcome: 4 Time to first seizure after randomisation - stratified by epilepsy type
Study or subgroup Topiramate (TPM)
Carbamazepine
(CBZ) log [Hazard Ratio] Hazard Ratio Weight Hazard Ratio
N N (SE) IV,Fixed,95% CI IV,Fixed,95% CI
1 Generalised Onset or Unclassified Epilepsy
Privitera 2003 48 25 0.58794 (0.3887) 3.9 % 1.80 [ 0.84, 3.86 ]
SANAD A 2007 46 34 -0.20276 (0.27965) 7.5 % 0.82 [ 0.47, 1.41 ]
Subtotal (95% CI) 94 59 11.4 % 1.07 [ 0.69, 1.67 ]
Heterogeneity: Chi2 = 2.73, df = 1 (P = 0.10); I2 =63%
Test for overall effect: Z = 0.29 (P = 0.77)
2 Partial Onset
Privitera 2003 218 104 0.21047 (0.1789) 18.3 % 1.23 [ 0.87, 1.75 ]
SANAD A 2007 312 328 0.0881 (0.09125) 70.3 % 1.09 [ 0.91, 1.31 ]
Subtotal (95% CI) 530 432 88.6 % 1.12 [ 0.96, 1.31 ]
Heterogeneity: Chi2 = 0.37, df = 1 (P = 0.54); I2 =0.0%
Test for overall effect: Z = 1.39 (P = 0.16)
Total (95% CI) 624 491 100.0 % 1.11 [ 0.96, 1.29 ]
Heterogeneity: Chi2 = 3.14, df = 3 (P = 0.37); I2 =4%
Test for overall effect: Z = 1.41 (P = 0.16)
Test for subgroup differences: Chi2 = 0.04, df = 1 (P = 0.85), I2 =0.0%
0.01 0.1 1 10 100
Favours Topiramate Favours Carbamazepine
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Analysis 1.5. Comparison 1 Topiramate monotherapy (TPM) versus Carbamazepine (CBZ) monotherapy,
Outcome 5 Time to 12 month remission of seizures.
Review: Topiramate versus carbamazepine monotherapy for epilepsy: an individual participant data review
Comparison: 1 Topiramate monotherapy (TPM) versus Carbamazepine (CBZ) monotherapy
Outcome: 5 Time to 12 month remission of seizures
Study or subgroup Topiramate (TPM)
Carbamazepine
(CBZ) log [Hazard Ratio] Hazard Ratio Weight Hazard Ratio
N N (SE) IV,Fixed,95% CI IV,Fixed,95% CI
Privitera 2003 266 129 -0.19684 (0.24411) 12.3 % 0.82 [ 0.51, 1.33 ]
SANAD A 2007 358 362 -0.15263 (0.09161) 87.7 % 0.86 [ 0.72, 1.03 ]
Total (95% CI) 624 491 100.0 % 0.85 [ 0.72, 1.01 ]
Heterogeneity: Chi2 = 0.03, df = 1 (P = 0.87); I2 =0.0%
Test for overall effect: Z = 1.84 (P = 0.065)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours Carbamazepine Favours Topiramate
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Analysis 1.6. Comparison 1 Topiramate monotherapy (TPM) versus Carbamazepine (CBZ) monotherapy,
Outcome 6 Time to 12 month remission of seizures - stratified by epilepsy type.
Review: Topiramate versus carbamazepine monotherapy for epilepsy: an individual participant data review
Comparison: 1 Topiramate monotherapy (TPM) versus Carbamazepine (CBZ) monotherapy
Outcome: 6 Time to 12 month remission of seizures - stratified by epilepsy type
Study or subgroup Topiramate (TPM)
Carbamazepine
(CBZ) log [Hazard Ratio] Hazard Ratio Weight Hazard Ratio
N N (SE) IV,Fixed,95% CI IV,Fixed,95% CI
1 Generalised Onset or Unclassified Epilepsy
Privitera 2003 48 25 -0.90187 (0.54685) 2.5 % 0.41 [ 0.14, 1.19 ]
SANAD A 2007 46 34 0.07861 (0.25637) 11.3 % 1.08 [ 0.65, 1.79 ]
Subtotal (95% CI) 94 59 13.8 % 0.91 [ 0.58, 1.43 ]
Heterogeneity: Chi2 = 2.64, df = 1 (P = 0.10); I2 =62%
Test for overall effect: Z = 0.42 (P = 0.67)
2 Partial Onset
Privitera 2003 218 104 -0.01123 (0.2761) 9.7 % 0.99 [ 0.58, 1.70 ]
SANAD A 2007 312 328 -0.20509 (0.09859) 76.5 % 0.81 [ 0.67, 0.99 ]
Subtotal (95% CI) 530 432 86.2 % 0.83 [ 0.69, 1.00 ]
Heterogeneity: Chi2 = 0.44, df = 1 (P = 0.51); I2 =0.0%
Test for overall effect: Z = 1.97 (P = 0.049)
Total (95% CI) 624 491 100.0 % 0.84 [ 0.71, 1.00 ]
Heterogeneity: Chi2 = 3.19, df = 3 (P = 0.36); I2 =6%
Test for overall effect: Z = 1.99 (P = 0.047)
Test for subgroup differences: Chi2 = 0.12, df = 1 (P = 0.73), I2 =0.0%
0.01 0.1 1 10 100
Favours Carbamazepine Favours Topiramate
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Analysis 1.7. Comparison 1 Topiramate monotherapy (TPM) versus Carbamazepine (CBZ) monotherapy,
Outcome 7 Time to 6 month remission of seizures.
Review: Topiramate versus carbamazepine monotherapy for epilepsy: an individual participant data review
Comparison: 1 Topiramate monotherapy (TPM) versus Carbamazepine (CBZ) monotherapy
Outcome: 7 Time to 6 month remission of seizures
Study or subgroup Topiramate (TPM)
Carbamazepine
(CBZ) log [Hazard Ratio] Hazard Ratio Weight Hazard Ratio
N N (SE) IV,Fixed,95% CI IV,Fixed,95% CI
Privitera 2003 266 129 -0.13116 (0.15266) 22.6 % 0.88 [ 0.65, 1.18 ]
SANAD A 2007 358 362 -0.12073 (0.08253) 77.4 % 0.89 [ 0.75, 1.04 ]
Total (95% CI) 624 491 100.0 % 0.88 [ 0.77, 1.02 ]
Heterogeneity: Chi2 = 0.00, df = 1 (P = 0.95); I2 =0.0%
Test for overall effect: Z = 1.70 (P = 0.090)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours Carbamazepine Favours Topiramate
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Analysis 1.8. Comparison 1 Topiramate monotherapy (TPM) versus Carbamazepine (CBZ) monotherapy,
Outcome 8 Time to 6 month remission of seizures - stratified by epilepsy type.
Review: Topiramate versus carbamazepine monotherapy for epilepsy: an individual participant data review
Comparison: 1 Topiramate monotherapy (TPM) versus Carbamazepine (CBZ) monotherapy
Outcome: 8 Time to 6 month remission of seizures - stratified by epilepsy type
Study or subgroup Topiramate (TPM)
Carbamazepine
(CBZ) log [Hazard Ratio] Hazard Ratio Weight Hazard Ratio
N N (SE) IV,Fixed,95% CI IV,Fixed,95% CI
1 Generalised Onset or Unclassified Epilepsy
Privitera 2003 48 25 -0.48879 (0.33261) 4.8 % 0.61 [ 0.32, 1.18 ]
SANAD A 2007 46 34 0.22682 (0.24281) 9.0 % 1.25 [ 0.78, 2.02 ]
Subtotal (95% CI) 94 59 13.9 % 0.98 [ 0.67, 1.44 ]
Heterogeneity: Chi2 = 3.02, df = 1 (P = 0.08); I2 =67%
Test for overall effect: Z = 0.11 (P = 0.91)
2 Partial Onset
Privitera 2003 218 104 -0.05209 (0.17275) 17.9 % 0.95 [ 0.68, 1.33 ]
SANAD A 2007 312 328 -0.16987 (0.08833) 68.3 % 0.84 [ 0.71, 1.00 ]
Subtotal (95% CI) 530 432 86.1 % 0.86 [ 0.74, 1.01 ]
Heterogeneity: Chi2 = 0.37, df = 1 (P = 0.54); I2 =0.0%
Test for overall effect: Z = 1.85 (P = 0.064)
Total (95% CI) 624 491 100.0 % 0.88 [ 0.76, 1.01 ]
Heterogeneity: Chi2 = 3.73, df = 3 (P = 0.29); I2 =20%
Test for overall effect: Z = 1.76 (P = 0.079)
Test for subgroup differences: Chi2 = 0.34, df = 1 (P = 0.56), I2 =0.0%
0.01 0.1 1 10 100
Favours Carbamazepine Favours Topiramate
A D D I T I O N A L T A B L E S
Table 1. Demographic characteristics of trial participants (trials providing Individual Participant Data)
Partial seizures n (%) Male gender n (%) Abnormal neurologi-
cal
exam, n (%)
Age at entry (years),
mean (SD), range
Number of seizures in
prior
6 months, median,
range
CBZ TPM Miss-
ing
CBZ TPM Miss-
ing
CBZ TPM Miss-
ing
CBZ TPM Miss-
ing
CBZ TPM Miss-
ing
Priv-
itera
104
(81)
218
(82)
0 68
(52)
147
(55)
0 NA NA 395 35. 33. 0 4(0- 4 (0- 0
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Table 1. Demographic characteristics of trial participants (trials providing Individual Participant Data) (Continued)
2003 4 (18.
7), 6-
80
9 (18.
2), 6-
75
2400) 1346)
SANAD
A
2007
333
(88)
321
(85)
89 204
(55)
204
(55)
18 87
(24)
105
(28)
18 39.
3 (18.
4), 5-
82
38.
7 (18.
6), 5-
86
18 4 (0-
467)
4 (0-
393)
21
CBZ = carbamazepine, TPM = topiramate, NA = not available, SD = standard deviation
Table 2. Number of participants included in analyses (trials providing individual participant data)
Number randomised Time to withdrawal
of
randomised
treatment
Time to first seizure Time to 12-
month remission
Time to 6-
month remission
CBZ TPM Total CBZ TPM Total CBZ TPM Total CBZ TPM Total CBZ TPM Total
Priv-
itera
2003
129 266 395 129 266 395 129 266 395 129 266 395 129 266 395
SANAD
A
2007
1
378 378 756 368 366 734 362 358 720 362 358 720 362 358 720
Total 507 644 1151 497 632 1129 491 624 1115 491 624 1115 491 624 1115
CBZ = carbamazepine, TPM = topiramate
1. Withdrawal time missing for 22 participants and seizure data after follow up missing for 36 participants in SANAD A 2007
Table 3. Reasons for premature discontinuation (withdrawal of allocated treatment) in trials providing IPD
Study Privitera 2003 SANAD A 20075 Grand
Total
Reason1 Classifi-
cation
in analy-
sis
CBZ TPM
100 mg/
day
TPM
200 mg/
day
TPM
(pooled)
Total CBZ TPM Total
Com-
pleted
study
Censored 63 64 66 130 193 151 137 288 481
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Table 3. Reasons for premature discontinuation (withdrawal of allocated treatment) in trials providing IPD (Continued)
Adverse
event
Event 32 26 30 56 88 104 103 207 295
Ineffec-
tive treat-
ment
Event 10 18 13 31 41 43 55 98 139
Other
reason
(event)2
Event 7 9 8 17 24 10 16 26 50
Both in-
effective
treatment
and
adverse
events
Event 0 0 0 0 0 20 28 48 48
Remis-
sion
Censored 0 0 0 0 0 25 19 44 44
Other
rea-
son (cen-
sored)3
Censored 3 4 2 6 9 19 12 31 40
Partici-
pant
choice4
Event 5 9 7 16 21 6 8 14 35
Lost to
follow-up
Censored 9 6 4 10 19 0 0 0 19
Total censored 75 74 72 146 221 201 176 377 598
Total events 54 62 58 120 174 177 202 379 553
Grand total 129 136 130 266 395 378 378 756 1151
CBZ = carbamazepine, TPM = topiramate
1. Primary reason for discontinuation specified - participants may have withdrawn from allocated treatment for a combination of
reasons
2. Other treatment related withdrawals: drug-related death, pregnancy or perceived remission (SANAD A 2007). Specified only as
’other reason’ in Privitera 2003
3. Otherwithdrawals (not treatment related): epilepsy diagnosis changed and death not related to treatment (SANADA 2007). Specified
only as ’other reason’ in Privitera 2003
4. Withdrawal of consent/participant choice classified as an event in this review but censored in included trial (SANAD A 2007).
Sensitivity analysis classifying withdrawal of consent as a censored observation did not change conclusions (results available on request).
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5. Withdrawal reasons available for all participants in the two studies but withdrawal times missing for 22 participants in SANAD A
2007 (see Table 2). These 22 participants were not included in analysis of time to withdrawal of randomised treatment, but all 22
withdrew for reasons which would have been censored in analysis, therefore the impact of these missing participants on the analysis is
minor
Table 4. Sensitivity analysis by topiramate dose - Privitera 2003
Treat-
ment
N Com-
parator
N Total Time to treatment
withdrawal
Time to first
seizure
Time to 12-month
remission
Time to 6-month re-
mission
HR
(95%
CI)
P value HR
(95%
CI)
P value HR
(95%
CI)
P value HR
(95%
CI)
P value
Topira-
mate
(both
arms)
266 Carba-
mazepine
129 395 1.04 (0.
75, 1.43)
0.82 1.32 (0.
96, 1.81)
0.09 0.82 (0.
51, 1.33)
0.42 0.88 (0.
65, 1.18)
0.39
Topira-
mate
200mg
130 Carba-
mazepine
129 259 1.03 (0.
71, 1.48)
0.89 1.34 (0.
94, 1.91)
0.11 0.83 (0.
48, 1.44)
0.5 0.84 (0.
59, 1.18)
0.31
Topira-
mate
100mg
136 Carba-
mazepine
129 265 1.05 (0.
73, 1.52)
0.79 1.29 (0.
89, 1.86)
0.18 0.79 (0.
46, 1.37)
0.41 0.93 (0.
66, 1.31)
0.66
HR = hazard ratio, CI = confidence interval
Table 5. Summary of adverse events experienced
Study and
drug
Privitera 2003 SANAD A 2007
TPM 100 TPM 200 CBZ Total TPM CBZ Total
Number expe-
riencing
adverse events
120 114 111 345 283 260 543
Number of
adverse events
1063 1035 970 3068 2503 1339 3842
Num-
ber of adverse
events per per-
son (range)
1 to 40 1 to 30 1 to 37 NA 1 to 35 1 to 37 NA
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Table 5. Summary of adverse events experienced (Continued)
Number
of drug related
adverse events
1
578 613 537 1728 NA NA NA
Number of
adverse events
requiring ac-
tion/treat-
ment change2
76 90 72 238 705 529 1234
Num-
ber of partici-
pants needing
a treat-
ment change/
dose change2
27 31 32 90 185 173 358
CBZ = carbamazepine, NA: Not available; TPM = topiramate, TPM 100 = topiramate 100 mg/day, TPM 200 = topiramate 200 mg/
day (Privitera 2003)
1. Defined as event which are ’very likely,’ ’probably’ or ’possibly’ related in Privitera 2003. Not stated if events were drug related in
SANAD A 2007
2. Information given only for drug discontinuation in Privitera 2003. Information on drug discontinuation and dose change in SANAD
A 2007
Table 6. Most commonly reported adverse events
Most
com-
monly
re-
ported
ad-
verse
events
Privitera 2003 SANAD A 2007 Total
CBZ TPM 100 TPM 200 Total CBZ TPM Total CBZ TPM Total
EventsPpts EventsPpts EventsPpts EventsPpts EventsPpts EventsPpts EventsPpts EventsPpts EventsPpts EventsPpts
Ag-
gres-
sion
0 0 8 6 5 2 13 8 41 25 75 50 116 75 41 25 88 58 129 83
Anorexia/
weight
loss
32 16 45 26 54 34 131 76 16 14 126 82 142 96 48 30 225 142 273 172
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Table 6. Most commonly reported adverse events (Continued)
Anx-
i-
ety/
De-
pres-
sion
24 15 48 27 60 39 132 81 46 35 107 71 153 106 70 50 215 137 285 187
Apha-
sia
18 10 10 7 34 14 62 31 11 10 16 16 27 26 29 20 60 37 89 57
Ataxia
7 4 11 6 9 6 27 16 30 23 21 14 51 37 37 27 41 26 78 53
Chest
in-
fec-
tion/
bron-
chi-
tis
36 23 41 25 54 26 131 74 6 6 3 3 9 9 42 29 98 54 140 83
Cold/
fever/
in-
fluenza
14 13 20 11 15 15 49 39 3 3 4 4 7 7 17 16 39 30 56 46
Con-
cen-
tra-
tion
6 5 15 7 28 11 49 23 11 11 8 7 19 18 17 16 51 25 68 41
Con-
fu-
sion
6 4 5 4 10 6 21 14 33 25 45 34 78 59 39 29 60 44 99 73
Den-
tal
6 3 10 7 9 5 25 15 17 14 13 13 30 27 23 17 32 25 55 42
Dizzy/
faint
49 30 44 24 35 23 128 77 64 51 76 49 140 100 113 81 155 96 268 177
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Table 6. Most commonly reported adverse events (Continued)
Drowsy/
tired
130 60 97 51 79 45 306 156 267 187 188 139 455 326 397 247 364 235 761 482
Gas-
troin-
testi-
nal
dis-
tur-
bances
88 51 50 32 53 28 191 111 49 41 48 32 97 73 137 92 151 92 288 184
Headache
75 39 84 38 40 24 199 101 97 65 76 44 173 109 172 104 200 106 372 210
In-
creased/
wors-
ened
seizures
2 2 5 4 0 0 7 6 41 30 30 24 71 54 43 32 35 28 78 60
Kid-
ney/
uri-
nary
prob-
lems
11 6 15 7 22 12 48 25 10 10 21 15 31 25 21 16 58 34 79 50
Mem-
ory
8 6 19 10 26 12 53 28 71 48 92 62 163 110 79 54 137 84 216 138
Mood/
Be-
havioural
change
19 10 22 14 29 15 70 39 56 42 97 76 153 118 75 52 148 105 223 157
Nau-
sea/
vom-
it-
ing
57 35 21 19 27 23 105 77 54 49 32 29 86 78 111 84 80 71 191 155
Pain
26 19 14 9 39 19 79 47 15 13 20 17 35 30 41 32 73 45 114 77
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Table 6. Most commonly reported adverse events (Continued)
Pins
and
nee-
dles
17 5 116 38 135 45 268 88 23 17 205 148 228 165 40 22 456 231 496 253
Rash
61 35 42 22 25 17 128 74 99 81 54 44 153 125 160 116 121 83 281 199
Sleep
prob-
lems/
night-
mares
14 6 24 14 23 12 61 32 24 16 40 30 64 46 38 22 87 56 125 78
Vi-
sion
7 5 8 5 3 3 18 13 33 28 24 23 57 51 40 33 35 31 75 64
Weight
gain
8 3 5 4 0 0 13 7 42 27 25 15 67 42 50 30 30 19 80 49
CBZ = carbamazepine, TPM = topiramate, TPM 100 = topiramate 100 mg/day, TPM 200 = topiramate 200 mg/day (Privitera 2003);
Events = number of adverse events reported; Ppts = number of participants reporting the adverse event (a participant could report the
same type of adverse event multiple times). Less commonly reported adverse events are not summarised in this table but details are
available on request from the review authors. General terminology for the type of adverse events was defined by the review authors
based on the individual participant data provided
A P P E N D I C E S
Appendix 1. Cochrane Epilepsy Group Specialized Register search strategy
#1 Topiram* or Tipiramate or Topamax
#2 MeSH DESCRIPTOR Carbamazepine Explode All
#3 Carbamezepin* or CBZ or SPD417 or Amizepine or “Apo-Carbamazepine” or Atretol or Biston or Calepsin or Carbagen or
Carbamazepen* or Carbatrol or Carbazepin* or Carbelan or Epitol or Equetro or Finlepsin or Karbamazepin or Lexin or Neurotol
or “Novo-Carbamaz” or “Nu-Carbamazepine” or Sirtal or Stazepin or Stazepine or “Taro-Carbamazepine” or Tegretal or Tegretol or
Telesmin or Teril or Timonil
#4 #2 OR #3
#5 #1 AND #4 AND INREGISTER
#6 ((adjunct* or “add-on” or “add on” or adjuvant* or combination* or polytherap*) not (monotherap* or alone or singl*)):TI
#7 #5 NOT #6
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Appendix 2. CENTRAL via CRSO search strategy
#1 (qudexy OR topamax OR topiram* OR tpm):TI,AB,KY
#2 MESH DESCRIPTOR Carbamazepine EXPLODE ALL TREES
#3 (biston OR carbamazepin* OR carbatrol OR cbz OR epitol OR equetro OR neurotop OR tegretol OR teril OR timonil):TI,AB,KY
#4 #2 OR #3
#5 (epilep* OR seizure* OR convuls*):TI,AB,KY
#6 MESH DESCRIPTOR Epilepsy EXPLODE ALL TREES
#7 MESH DESCRIPTOR Seizures EXPLODE ALL TREES
#8 #5 OR #6 OR #7
#9 #1 AND #4 AND #8
#10 ((adjunct* OR “add-on” OR “add on” OR adjuvant* OR combination* OR polytherap*) NOT (monotherap* or alone or singl*)):
TI
#11 #9 NOT #10
Appendix 3. MEDLINE (Ovid) search strategy
This strategy is based on the Cochrane Highly Sensitive Search Strategy for identifying randomized trials (Lefebvre 2011).
1. (Topiram$ or Tipiramate or Topamax).mp.
2. exp Carbamazepine/
3. (Carbamezepin$ or CBZ or SPD417 or Amizepine or “Apo-Carbamazepine” or Atretol or Biston or Calepsin or Carbagen or
Carbamazepen$ or Carbatrol or Carbazepin$ or Carbelan or Epitol or Equetro or Finlepsin or Karbamazepin or Lexin or Neurotol
or “Novo-Carbamaz” or “Nu-Carbamazepine” or Sirtal or Stazepin or Stazepine or “Taro-Carbamazepine” or Tegretal or Tegretol or
Telesmin or Teril or Timonil).mp.
4. 2 or 3
5. exp Epilepsy/
6. exp Seizures/
7. (epilep$ or seizure$ or convuls$).tw.
8. 5 or 6 or 7
9. exp *Pre-Eclampsia/ or exp *Eclampsia/
10. 8 not 9
11. (randomized controlled trial or controlled clinical trial or pragmatic clinical trial).pt. or (randomi?ed or placebo or randomly).ab.
12. clinical trials as topic.sh.
13. trial.ti.
14. 11 or 12 or 13
15. exp animals/ not humans.sh.
16. 14 not 15
17. 1 and 4 and 10 and 16
18. ((adjunct$ or “add-on” or “add on” or adjuvant$ or combination$ or polytherap$) not (monotherap$ or alone or singl$)).ti.
19. 17 not 18
20. remove duplicates from 19
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